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https://doi.org/10.1016/j.cell.2020.10.043SUMMARYA safe, effective, and scalable vaccine is needed to halt the ongoing SARS-CoV-2 pandemic.We describe the
structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective
antibody responses against SARS-CoV-2 in mice. The nanoparticle vaccines display 60 SARS-CoV-2 spike
receptor-binding domains (RBDs) in a highly immunogenic array and induce neutralizing antibody titers
10-fold higher than the prefusion-stabilized spike despite a 5-fold lower dose. Antibodies elicited by the
RBD nanoparticles target multiple distinct epitopes, suggesting theymay not be easily susceptible to escape
mutations, and exhibit a lower binding:neutralizing ratio than convalescent human sera, which may minimize
the risk of vaccine-associated enhanced respiratory disease. The high yield and stability of the assembled
nanoparticles suggest that manufacture of the nanoparticle vaccines will be highly scalable. These results
highlight the utility of robust antigen display platforms and have launched cGMP manufacturing efforts to
advance the SARS-CoV-2-RBD nanoparticle vaccine into the clinic.INTRODUCTION
The recent emergence of a previously unknown virus in Wuhan,
China has resulted in the ongoing coronavirus disease 2019
(COVID-19) pandemic that has caused more than 34,000,000 in-
fections and 1,000,000 fatalities as of October 2, 2020 (WHO).
Rapid viral isolation and sequencing revealed by January 2020
that the newly emerged zoonotic pathogen was a coronavirus
closely related to SARS-CoV and was therefore named SARS-Cell 183, 1367–1382, Novem
This is an open access article undCoV-2 (Zhou et al., 2020c; Zhu et al., 2020b). SARS-CoV-2 is
believed to have originated in bats based on the isolation of
the closely related RaTG13 virus from Rhinolophus affinis
(Zhou et al., 2020c) and the identification of the RmYN02
genome sequence in metagenomics analyses of Rhinolophus
malayanus (Zhou et al., 2020b), both from Yunnan, China.
Similar to other coronaviruses, SARS-CoV-2 entry into host
cells is mediated by the transmembrane spike (S) glycoprotein,
which forms prominent homotrimers protruding from the viralber 25, 2020 ª 2020 The Authors. Published by Elsevier Inc. 1367
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Cryoelectron microscopy structures of SARS-CoV-2 S revealed
its shared architecture with SARS-CoV S and provided a blue-
print for the design of vaccines and antivirals (Walls et al.,
2020; Wrapp et al., 2020). Both SARS-CoV-2 S and SARS-CoV
S bind to angiotensin-converting enzyme 2 (ACE2), which serves
as entry receptor (Hoffmann et al., 2020; Letko et al., 2020; Li
et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Zhou et al.,
2020c). Structures of the SARS-CoV-2 S receptor-binding
domain (RBD) in complex with ACE2 defined key residues
involved in recognition and guide surveillance studies aiming to
detect the emergence of mutants with altered binding affinity
for ACE2 or distinct antigenicity (Lan et al., 2020; Shang et al.,
2020; Starr et al., 2020; Wang et al., 2020b; Yan et al., 2020).
As the coronavirus S glycoprotein is surface-exposed and ini-
tiates infection, it is the main target of neutralizing antibodies
(Abs) upon infection and the focus of vaccine design (Tortorici
and Veesler, 2019). S trimers are extensively decorated with
N-linked glycans that are important for proper folding (Rossen
et al., 1998) and for modulating accessibility to host proteases
and neutralizing Abs (Walls et al., 2016b; 2017; 2019; Watanabe
et al., 2020; Xiong et al., 2018; Yang et al., 2015). We previously
characterized potent human neutralizing Abs from rare memory
B cells of individuals infectedwith SARS-CoV (Rockx et al., 2008;
Traggiai et al., 2004) or Middle East respiratory syndrome
(MERS)-CoV (Corti et al., 2015) in complex with their respective
S glycoproteins to provide molecular-level information on the
mechanism of competitive inhibition of RBD attachment to
host receptors (Walls et al., 2019). Passive administration of
these Abs protected mice from lethal challenges with MERS-
CoV, SARS-CoV, and closely related viruses, indicating that
they represent a promising therapeutic strategy against corona-
viruses (Corti et al., 2015; Menachery et al., 2015; 2016; Rockx
et al., 2008). We identified a human monoclonal Ab that neutral-
izes SARS-CoV-2 and SARS-CoV through recognition of the
RBD from the memory B cells of a SARS survivor obtained 10
years after recovery (Pinto et al., 2020). We recently showed
that the SARS-CoV-2 RBD is immunodominant, comprises mul-
tiple distinct antigenic sites, and is the target of 90% of the
neutralizing activity present in COVID-19 convalescent sera (Pic-
coli et al., 2020). These findings showed that the RBD is a prime
target of neutralizing Abs upon natural CoV infection, in agree-
ment with other reports of the isolation of RBD-targeted neutral-
izing Abs from COVID-19 convalescent patients (Barnes et al.,
2020; Brouwer et al., 2020; Liu et al., 2020; Robbiani
et al., 2020; Seydoux et al., 2020; Tortorici et al., 2020; Wang
et al., 2020a; Wu et al., 2020) and the demonstration that they
provide in vivo protection against SARS-CoV-2 challenge in
small animals and nonhuman primates (Alsoussi et al., 2020;
Tortorici et al., 2020; Wu et al., 2020; Zost et al., 2020). Collec-
tively, these observations, along with a correlation between the
presence of RBD-directed Abs and neutralization potency of
COVID-19 patient plasma (Robbiani et al., 2020), motivate the
use of the SARS-CoV-2 RBD as a vaccine immunogen.
Vaccine development efforts responding to the COVID-19
pandemic have made extensive use of platform technologies
for antigen design, antigen display, and vaccine delivery (Kane-
kiyo et al., 2019a). For example, existing nucleic acid and1368 Cell 183, 1367–1382, November 25, 2020vectored vaccine platforms enabled rapid entry into the clinic
with vaccines encoding SARS-CoV-2 S antigens (Folegatti
et al., 2020; Jackson et al., 2020; Mulligan et al., 2020; Sahin
et al., 2020; Yu et al., 2020; Zhu et al., 2020a). However, the
safety, efficacy, and scalability of these vaccine modalities are
not fully understood, as there are currently noDNA ormRNA vac-
cines licensed for human use, and the first viral vector vaccine
was approved only within the last few months (Anywaine et al.,
2019). In contrast, self-assembling or particulate protein immu-
nogens are a clinically validated vaccine modality with a proven
track record of safety and efficacy in humans (López-Sagaseta
et al., 2015). For example, virus-like particle (VLP) vaccines for
human papillomavirus (HPV) and hepatitis B virus (HBV) are
among the most effective subunit vaccines known, with data
suggesting that the HPV vaccines in particular provide potent,
durable immunity even after a single vaccination (Kreimer
et al., 2018). Recently, self-assembling protein platforms for het-
erologous antigen display have matured significantly, and
several protein nanoparticle vaccines displaying viral glycopro-
tein antigens are currently being evaluated in clinical trials
(NCT03547245, NCT03186781, NCT03814720). A new develop-
ment in this area has been the emergence of computationally de-
signed protein nanoparticles as a robust and versatile platform
for multivalent antigen presentation (Bale et al., 2016; Hsia
et al., 2016; King et al., 2012; Ueda et al., 2020). In preclinical
studies, vaccine candidates based on designed protein nano-
particles have significantly improved the potency or breadth of
Ab responses against numerous antigens, including prefusion
respiratory syncytial virus (RSV) F (Marcandalli et al., 2019),
HIV-1 envelope (Brouwer et al., 2019), influenza hemagglutinin
(Boyoglu-Barnum et al., 2020), and P. falciparum cysteine-rich
protective antigen (CyRPA) (Bruun et al., 2018), relative to either
soluble antigen or commercial vaccine comparators.
Here, we report designed protein nanoparticle vaccines multi-
valently displaying the SARS-CoV-2 RBD that elicit potent and
protective Ab responses in mice, with neutralizing titers an order
of magnitude higher at a 5-fold lower dose than soluble
prefusion-stabilized S, while also exhibiting a significantly lower
binding:neutralizing ratio than convalescent human sera. We
further show that nanoparticle vaccine-elicited Abs recognize
multiple distinct RBD epitopes targeted by known neutralizing
Abs, suggesting that they may not be easily susceptible to
escape mutations.
RESULTS
Design, In Vitro Assembly, and Characterization of
SARS-CoV-2 RBD Nanoparticle Immunogens
To design vaccine candidates that induce potent neutralizing
Ab responses, we focused on the RBD of the SARS-CoV-
2 S glycoprotein (Figures 1A and 1B). To overcome the limited
immunogenicity of this small, monomeric antigen, we multiva-
lently displayed the RBD on the exterior surface of the two-
component protein nanoparticle I53-50 (Bale et al., 2016).
I53-50 is a computationally designed, 28 nm-wide, 120-subunit
complex with icosahedral symmetry constructed from trimeric
(I53-50A) and pentameric (I53-50B) components (all amino acid
sequences provided in Data S1). The nanoparticle can be
Figure 1. Design, In Vitro Assembly, and
Characterization of SARS-CoV-2 RBD
Nanoparticle Immunogens
(A) Molecular surface representation of the SARS-
CoV-2 S-2P trimer in the prefusion conformation
(PDB 6VYB). Each protomer is colored distinctly,
and N-linked glycans are rendered dark blue (the
glycan at position N343 was modeled based on
PDB 6WPS and the receptor-binding motif [RBM]
wasmodeled from PDB 6M0J). A single open RBD
is boxed.
(B) Molecular surface representation of the SARS-
CoV-2 S RBD, including the N-linked glycans at
positions 331 and 343. The ACE2 receptor-bind-
ing site or RBM is indicated with a black outline.
(C) Structural models of the trimeric RBD-I53-50A
(RBD in light blue and I53-50A in light gray) and
pentameric I53-50B (orange) components. Upon
mixing in vitro, 20 trimeric and 12 pentameric
components assemble to form nanoparticle im-
munogens with icosahedral symmetry. Each
nanoparticle displays 60 copies of the RBD.
(D) Structural model of the RBD-12GS-I53-50
nanoparticle immunogen. Although a single
orientation of the displayed RBD antigen and
12-residue linker are shown for simplicity, these
regions are expected to be flexible relative to the
I53-50 nanoparticle scaffold.
(E) DLS of the RBD-8GS-, RBD-12GS-, and RBD-
16GS-I53-50 nanoparticles compared to unmod-
ified I53-50 nanoparticles.
(F) Representative electron micrographs of nega-
tively stained RBD-8GS-, RBD-12GS-, and RBD-
16GS-I53-50 nanoparticles. The samples were
imaged after one freeze/thaw cycle. Scale bars,
100 nm.
(G) Hydrogen/deuterium-exchange mass spec-
trometry of monomeric RBD versus trimeric RBD-
8GS-I53-50A component, represented here as a
butterfly plot, confirms preservation of the RBD
conformation, including at epitopes recognized by
known neutralizing Abs. In the plot, each point
along the horizontal sequence axis represents a
peptide where deuterium uptake was monitored
from 3 s to 20 h. Error bars shown on the butterfly
plot indicate standard deviations from two
experimental replicates. The difference plot below
demonstrates that monomeric RBD and RBD-
8GS-I53-50A are virtually identical in local struc-
tural ordering across the RBD.
(H) Pie charts summarizing the glycan composition at the N-linked glycosylation sites N331 and N343 in five protein samples: monomeric RBD, S-2P trimer, RBD-
8GS-, RBD-12GS-, and RBD-16GS-I53-50A trimeric components. The majority of the complex glycans at both sites were fucosylated; minor populations of non-
fucosylated glycans are indicated by dashed white lines. Oligo, oligomannose.
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and purified I53-50A and I53-50B, a feature that has facilitated
its use as a platform for multivalent antigen presentation
(Brouwer et al., 2019; Marcandalli et al., 2019). The RBD (resi-
dues 328–531) was genetically fused to I53-50A using linkers
comprising 8, 12, or 16 glycine and serine residues (hereafter
referred to as RBD-8GS-, RBD-12GS-, or RBD-16GS-I53-50A)
to enable flexible presentation of the antigen extending from
the nanoparticle surface (Figure 1C). All RBD-I53-50A constructs
were recombinantly expressed using mammalian (Expi293F)
cells to ensure proper folding and glycosylation of the viral anti-gen. Initial yields of purified RBD-I53-50A proteins (30 mg pu-
rified protein per liter Expi293F cells) were 20-fold higher than
for the prefusion-stabilized S-2P trimer (Kirchdoerfer et al., 2018;
Pallesen et al., 2017; Walls et al., 2020; Wrapp et al., 2020)
(1.5 mg/L) and increased to60 mg/L following promoter opti-
mization. The RBD-I53-50A proteins were mixed with pentame-
ric I53-50B purified from E. coli in a1:1 molar ratio (subunit:su-
bunit) to initiate nanoparticle assembly (Figure 1D).
Size-exclusion chromatography (SEC) of the SARS-CoV-2
RBD-I53-50 nanoparticles revealed predominant peaks corre-
sponding to the target icosahedral assemblies and smaller peaksCell 183, 1367–1382, November 25, 2020 1369
Table 1. Antigenic Characterization of SARS-CoV-2 RBD-I53-50A Components
Antigen Binder kon (M–1 s–1) koff (s–1) KD (nM)
SARS-CoV-2 RBD hACE2 7 3 104 ± 5 3 102 5 3 103 ± 1 3 105 69 ± 0.5
CR3022 Fab 2 3 105 ± 2 3 103 9 3 103 ± 3 3 105 45 ± 0.5
RBD-8GS-I53-50A hACE2 6 3 104 ± 4 3 102 4 3 103 ± 1 3 105 70 ± 0.5
CR3022 Fab 2 3 105 ± 1 3 103 1 3 102 ± 3 3 105 57 ± 0.4
RBD-12GS-I53-50A hACE2 6 3 104 ± 4 3 102 5 3 103 ± 1 3 105 78 ± 0.5
CR3022 Fab 2 3 105 ± 2 3 103 9 3 103 ± 2 3 105 42 ± 0.4
RBD-16GS-I53-50A hACE2 6 3 104 ± 4 3 102 4 3 102 ± 1 3 105 66 ± 0.4
CR3022 Fab 2 3 105 ± 1 3 103 1 3 102 ± 2 3 105 56 ± 0.4
Each experiment was performed at least twice, and the values and fitting errors presented are derived from a representative experiment. The corre-
sponding binding curves and fits are presented in Figure S2.
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(Figures S1A and S1B). Dynamic light scattering (DLS) and nega-
tive stain electronmicroscopy (nsEM) confirmed the homogeneity
and monodispersity of the various RBD-I53-50 nanoparticles,
both before and after freeze/thaw (Figures 1E, 1F, and S1C).
The average hydrodynamic diameter and percent polydispersity
measured by DLS for RBD-8GS-, RBD-12GS-, and RBD-16GS-
I53-50 before freeze/thaw were 38.5 (27%), 37 (21%), and 41
(27%) nm, respectively, compared to 30 (22%) nm for unmodified
I53-50 nanoparticles. Hydrogen/deuterium-exchange mass
spectrometry confirmed that display of the RBD on the trimeric
RBD-8GS-I53-50A component preserved the conformation of
the antigen and structural order of several distinct antibody epi-
topes (Figures 1G and S1D). Finally, we used glycoproteomics
to show that all three RBD-I53-50A components were N-glycosy-
lated at positions N331 and N343 similarly to the SARS-CoV-2
S-2P ectodomain trimer (Watanabe et al., 2020), again suggesting
that the displayed antigen retained its native antigenic properties,
which is key in light of the participation of glycans in the epitopes
of several potent neutralizing Abs (Pinto et al., 2020; Tortorici
et al., 2020) (Figures 1H and S1E).
Antigenic Characterization of SARS-CoV-2 RBD-I53-50
Nanoparticle Components and Immunogens
We used recombinant human ACE2 ectodomain and two S-spe-
cific mAbs (CR3022 and S309) to characterize the antigenicity of
the RBD when fused to I53-50A as well as the accessibility of
multiple RBD epitopes in the context of the assembled nanopar-
ticle immunogens. CR3022 and S309 were both isolated from
individuals infected with SARS-CoV and cross-react with the
SARS-CoV-2 RBD. CR3022 is a weakly neutralizing Ab that
binds to a conserved, cryptic epitope in the RBD (site II) that be-
comes accessible upon opening of two neighboring RBDs but is
distinct from the RBM (site I), the surface of the RBD that inter-
acts with ACE2 (Huo et al., 2020; Piccoli et al., 2020; ter Meulen
et al., 2006; Yuan et al., 2020). S309 neutralizes both SARS CoV
and SARS-CoV-2 by binding to a glycan-containing epitope (site
IV) that is conserved among sarbecoviruses and accessible in
both the open and closed prefusion S conformational states
(Pinto et al., 2020).
We used biolayer interferometry (BLI) to confirm the binding
affinities of the monomeric human ACE2 (hACE2) ectodomain
and the CR3022 Fab for the monomeric RBD. Equilibrium disso-1370 Cell 183, 1367–1382, November 25, 2020ciation constants (KD) of these reagents for immobilized RBD-
I53-50A fusion proteins closely matched those obtained for the
monomeric RBD (Huo et al., 2020; Starr et al., 2020; Yuan
et al., 2020) (Table 1; Figure S2). These data further confirm
that the RBD-I53-50A fusion proteins display the RBD in its
native conformation.
We previously observed that the magnitude and quality of
nanoparticle immunogen-elicited Ab responses can be modu-
lated by the accessibility of specific epitopes in the context of
a dense, multivalent antigen array, most likely through steric
crowding (Brouwer et al., 2019). To evaluate this possibility, we
measured the binding of the nanoparticle immunogens to immo-
bilized dimeric macaque ACE2 (mACE2-Fc) and the CR3022 and
S309mAbs, the latter of which roughlymimics the B cell receptor
(BCR)-antigen interaction that is central to B cell activation. This
approach does not allow the calculation of KD values due to the
multivalent nature of the interactions but does enable qualitative
comparisons of epitope accessibility in different nanoparticles.
We compared the full-valency nanoparticles displaying 60
RBDs to a less dense antigen array by leveraging the versatility
of in vitro assembly to prepare nanoparticle immunogens dis-
playing the RBD antigen at 50% valency (30 RBDs per nano-
particle) (Figure S3). This was achieved by adding pentameric
I53-50B to an equimolar mixture of RBD-I53-50A and unmodi-
fied I53-50A (lacking the fused antigen). We found that all of
the RBD nanoparticles bound well to the immobilized mACE2-
Fc, CR3022, and S309 (Figure 2A). Although there were no
consistent trends among the 50% and 100% valency RBD-
8GS- and RBD-12GS-I53-50 nanoparticles, the 100% valency
RBD-16GS-I53-50 nanoparticles resulted in the highest binding
signals against all three binders (Figure 2B). It is possible that the
longer linker in the RBD-16GS-I53-50 nanoparticle enables bet-
ter access to the epitopes targeted by ACE2, CR3022, and S309,
although our data cannot rule out other possible explanations.
We conclude that multiple distinct epitopes targeted by neutral-
izing antibodies are exposed and accessible for binding in the
context of the RBD antigen array presented on the nanoparticle
exterior.
Physical and Antigenic Stability of RBD Nanoparticle
Immunogens and S-2P Trimer
Although subunit vaccines based on recombinant protein
antigens have several intrinsic advantages over other vaccine
Figure 2. Antigenic Characterization of SARS-CoV-2 RBD-I53-50 Nanoparticle Immunogens
(A) Biolayer interferometry of immobilized mACE2-Fc, CR3022 mAb, and S309 mAb binding to RBD-8GS-, RBD-12GS-, and RBD-16GS-I53-50 nanoparticles
displaying the RBD antigen at 50% or 100% valency. The monomeric SARS-CoV-2 RBD was included in each experiment as a reference.
(B) Themagnitude of the binding response at 880 s, near the end of the association phase, is plotted for each experiment in (A) to enable comparison of the binding
signal obtained from each nanoparticle.
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bility during manufacture, storage, and distribution (Kumru et al.,
2014). We first used chemical denaturation in guanidine hydro-
chloride (GdnHCl) to compare the stability of the RBD-I53-50A
fusion proteins and RBD-12GS-I53-50 nanoparticle immunogen
to recombinant monomeric RBD and the S-2P ectodomain
trimer (Figure 3A). Fluorescence emission spectra from samples
incubated in 0–6.5 M GdnHCl revealed that all three RBD-I53-
50A fusion proteins and the RBD-12GS-I53-50 nanoparticle un-
dergo a transition between 4 and 5 M GdnHCl that indicates at
least partial unfolding, whereas the S-2P trimer showed a transi-
tion at lower GdnHCl concentrations (between 2 and 4 M). The
monomeric RBD exhibited a less cooperative, broad unfolding
transition spanning 0 to 5 M GdnHCl. We then used a suite of
analytical assays to monitor physical and antigenic stability
over 4 weeks post-purification at three temperatures: <70C,
2C–8C, and 22C–27C (Figures 3B–3E; Data S2). Consistent
with previous reports, the monomeric RBD proved quite stable,
yielding little change in appearance by SDS-PAGE (Figure S4A),
mACE2-Fc and CR3022 binding (Figure S4B), or the ratio of UV/
vis absorption at 320/280 nm, ameasure of particulate scattering
(Figure S4C). As reported recently (Edwards et al., 2020; Hsieh
et al., 2020), the S-2P trimer was unstable at 2C–8C, exhibiting
clear signs of unfolding by nsEM even at early time points (Fig-
ure S3D; Data S2). Instead, S-2Pmaintained its structure consid-
erably better at 22C–27C until the latest time point (28 days),
when unfolding was apparent by nsEM and absorbance mea-
surements indicated some aggregation (Figure S4C). All three
RBD-I53-50A components were highly stable, exhibiting no sub-
stantial change by any readout at any time point (Data S2).Finally, the RBD-12GS-I53-50 nanoparticle was also stable
over the 4-week study, showing changes only in UV/vis absor-
bance, where an unusual peak near 320 nm appeared after
7 days at 22C–27C, but was absent at day 28, possibly due
to settling of aggregated material in unmixed samples (Data
S2). Nevertheless, electron micrographs and DLS of well-mixed
RBD-12GS-I53-50 nanoparticle samples consistently showed
monodisperse, well-formed nanoparticles at all temperatures
over the 4-week period (Figures S4D and S4E; Data S2). Collec-
tively, these data show that the RBD-I53-50A components and
the RBD-12GS-I53-50 nanoparticle have high physical and anti-
genic stability, superior to the S-2P ectodomain trimer.
RBD-I53-50 Nanoparticle Immunogens Elicit Potent
Neutralizing Antibody Responses in BALB/c and Human
Immune Repertoire Mice
We compared the immunogenicity of the three RBD-I53-50
nanoparticles, each displaying the RBD at either 50% or 100%
valency, to the S-2P ectodomain trimer and the monomeric
RBD in BALB/c mice. Groups of 10 mice were immunized intra-
muscularly at weeks 0 and 3 with AddaVax-adjuvanted formula-
tions containing either 0.9 or 5 mg of SARS-CoV-2 antigen in
either soluble or particulate form. Three weeks post-prime, all
RBD nanoparticles elicited robust S-specific Ab responses
with geometric mean titers (GMTs) ranging from 8 3 102 and
13 104 (Figure 4A; Data S3 and S4). In contrast, the monomeric
RBD and the low dose of S-2P trimer did not induce detectable
levels of S-specific Abs, while the high dose of S-2P trimer
elicited weak responses. Following a second immunization,
we observed an enhancement of S-specific Ab titers for allCell 183, 1367–1382, November 25, 2020 1371
Figure 3. Physical and Antigenic Stability of RBD Nanoparticle Immunogens and S-2P Trimer
(A) Chemical denaturation by guanidine hydrochloride. The ratio of intrinsic tryptophan fluorescence emission at 350/320 nm was used to monitor retention of
protein tertiary structure. Major transitions are indicated by shaded regions. Representative data from one of three independent experiments are shown.
(B) Summary of SDS-PAGE and nsEM stability data over 4 weeks. SDS-PAGE showed no detectable degradation in any sample. nsEM revealed substantial
unfolding of the S-2P trimer at 2C–8C after 3 days incubation, and at 22C–27C after 4 weeks. N/A, not assessed.
(C) Summary of antigenicity data over 4 weeks. The antigens were analyzed for mACE2-Fc (solid lines) and CR3022 mAb (dashed lines) binding by biolayer
interferometry after storage at the various temperatures. The plotted value represents the amplitude of the signal near the end of the association phase normalized
to the corresponding <70C sample at each time point.
(D) Summary of UV/vis stability data over 4 weeks. The ratio of absorbance at 320/280 nm is plotted as a measure of particulate scattering. Only the S-2P trimer
and the RBD-12GS-I53-50 nanoparticle showed any increase in scattering and only at ambient temperature.
(E) DLS of the RBD-12GS-I53-50 nanoparticle indicated a monodisperse species with no detectable aggregate at all temperatures and time points.
The data in (B–E) are from a 4-week real-time stability study that was performed once.
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OPEN ACCESS ArticleRBD nanoparticle groups, with GMTs ranging from 1 3 105 to
2 3 106 (Figure 4B; Data S3 and S4). These levels of S-specific
Abs matched or exceeded most samples from a panel of 30
COVID-19 human convalescent sera (HCS) from Washington
state and the benchmark 20/130 COVID-19 plasma from
National Institute for Biological Standards and Control (NIBSC)
(Figure 4A–B; see STAR Methods). Levels of S-specific Abs
have been shown to correlate with disease severity (Piccoli
et al., 2020); the panel of HCS we used included samples from1372 Cell 183, 1367–1382, November 25, 20204 hospitalized patients and 26 patients that were symptomatic
but not hospitalized (Data S5). Immunization with two 5 mg doses
of S-2P trimer induced S-specific Ab responses 1–2 orders of
magnitude weaker than the RBD nanoparticles, and the mono-
meric RBD did not elicit detectable antigen-specific Abs after
two immunizations. As expected, we also detected an Ab
response to the I53-50 scaffold, which was constant in magni-
tude across all RBD nanoparticle groups (Figure S5; Data S4).
These data indicate that multivalent display of the RBD on a
Figure 4. RBD-I53-50 Nanoparticle Immunogens Elicit High Ab Ti-
ters in BALB/c and Human Immune Repertoire Mice
(A and B) Post-prime (week 2) (A) and post-boost (week 5) (B) anti-S Ab binding
titers in BALB/c mice, measured by ELISA. Each symbol represents an indi-
vidual animal, and the GMT from each group is indicated by a horizontal line.
8GS, RBD-8GS-I53-50; 12GS, RBD-12GS-I53-50; 16GS, RBD-16GS-I53-50;
HCS, COVID-19 human convalescent sera. The open diamond in the HCSdata
is the benchmark NIBSC plasma (see STAR Methods). The inset depicts the
study timeline. The mouse immunization study was repeated twice, and
representative data are shown.
(C and D) Post-prime (week 2) (C) and post-boost (week 5) (D) anti-S Ab
binding titers in Kymab Darwin mice, which are transgenic for the non-re-
arranged human Ab variable and constant region germline repertoire,
measured by ELISA and plotted as in (A). The inset depicts the study timeline.
The mouse immunization study was performed once.
The dotted horizontal lines represent the lower limit of detection of the assay,
and the dotted vertical lines highlight that measurements on HCS used a
different secondary Ab than measurements on mouse sera. Raw data are
provided in Data S3, and statistical analyses are provided in Data S4.
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immunogenicity.
We prototyped potential human Ab responses to the RBD
nanoparticle immunogens using the Kymab proprietary Intelli-
Select Transgenic mouse platform (known as ‘‘Darwin’’) that is
transgenic for the non-rearranged human Ab variable and con-
stant region germline repertoire. In contrast to mice with
chimeric Ab loci that have been previously described (Lee
et al., 2014), the mice in the present study differed in that they
were engineered to express fully human kappa light chain
Abs. Groups of five Darwin mice were immunized intramuscu-
larly with S-2P trimer, 100% RBD-12GS-I53-50, or 100%
RBD-16GS-I53-50 nanoparticles at antigen doses of 0.9 mg
(nanoparticles only) or 5 mg (Figure 4C). All groups immunized
with RBD nanoparticles elicited S-directed Ab responses
post-prime (EC50 2 3 10
3–1x104) that were substantially
boosted by a second immunization at week 3 (EC50 ranging
from 4 3 105 to 8 3 105) (Figures 4C and 4D; Data S3 and
S4). In this animal model, the S-2P trimer elicited levels of
S-specific Abs comparable to the RBD nanoparticles after
each immunization.
We then evaluated the neutralizing activity elicited by each
immunogen using both pseudovirus and live virus neutralization
assays. In BALB/c mice, all RBD nanoparticle immunogens
elicited serum neutralizing Abs after a single immunization,
with reciprocal half-maximal inhibition dilutions (IC50) ranging
from 1 3 102 to 5 3 102 (GMT) in pseudovirus and 3 3 103 to
7 3 103 in live virus neutralization assays (Figures 5A and 5C;
Data S3 and S4). No significant differences in pseudovirus or
live virus neutralization were observed between low or high
doses of RBD-8GS-, RBD-12GS-, or RBD-16GS-I53-50 nano-
particles at 50% (pseudovirus neutralization only) or 100% va-
lency, in agreement with the S-specific Ab data. The GMT of
all three 100% valency RBD nanoparticle groups matched or
exceeded that of the panel of HCS tested in the pseudovirus
neutralization assay (Figure 5A). Immunization with monomeric
RBD or S-2P trimer did not elicit neutralizing Abs after a
single immunization, in line with the observed lack of S-directed
Ab responses and a previous study (Mandolesi et al., 2020) (Fig-
ures 5A and 5C). As in BALB/c mice, both high and low doses of
the RBD-I53-50 nanoparticles in Darwin mice elicited pseudovi-
rus neutralizing Ab titers (IC50 8 3 10
1 to 2.5 3 102) comparable
to HCS (IC50 13 10
2) after a single immunization, whereas 5 mg of
the S-2P trimer did not elicit detectable levels of neutralizing Abs
(Figure 5E; Data S3) despite eliciting similar levels of total S-spe-
cific Abs.
In both mouse models, a second immunization with the RBD-
I53-50 nanoparticles led to a large increase in neutralizing Ab
titers. In BALB/cmice, pseudovirus neutralization GMT reached
2 3 103 to 3 3 104, exceeding that of the HCS by 1–2 orders of
magnitude, and live virus neutralization titers reached 2 3 104
to 3 3 104 (Figures 5B and 5D). A second immunization with
5 mg of the S-2P trimer also strongly boosted neutralizing activ-
ity, although pseudovirus and live virus neutralization GMTs
(3 3 102 and 6 3 103, respectively) were still lower than in
sera from animals immunized with the RBD nanoparticles. The
increases between the S-2P trimer and the RBD nanoparticles
ranged from 7- to 90-fold and 4- to 9-fold in the pseudovirusCell 183, 1367–1382, November 25, 2020 1373
Figure 5. RBD-I53-50 Nanoparticle Immunogens Elicit Potent and Protective Neutralizing Ab Responses
(A and B) Serum pseudovirus neutralizing titers post-prime (A) and post-boost (B) from mice immunized with monomeric RBD, S-2P trimer, or RBD-I53-50
nanoparticles. Each circle represents the reciprocal IC50 of an individual animal. GMT for each group is indicated by a horizontal line. 8GS, RBD-8GS-I53-50;
12GS, RBD-12GS-I53-50; 16GS, RBD-16GS-I53-50; HCS, COVID-19 human convalescent sera. The open diamond in the HCS data is the benchmark NIBSC
plasma (see STAR Methods). The inset depicts the study timeline. The mouse immunization study was performed twice, and representative data from duplicate
measurements are shown.
(C and D) Serum live virus neutralizing titers post-prime (C) and post-boost (D) from mice immunized as described in (A).
(E and F) Serum pseudovirus neutralizing titers from Kymab Darwin mice post-prime (E) and post-boost (F), immunized as described in (A). The mouse immu-
nization study was performed once, and the neutralization assays were performed at least in duplicate.
(G and H) Seven weeks post-boost, eight BALB/c mice per group were challenged with SARS-CoV-2 MA. Two days post-challenge, viral titers in lung tissue (G)
and nasal turbinates (H) were assessed.
The dotted horizontal lines represent the lower limit of detection of the assays. Raw data are provided in Data S3, and statistical analyses are provided in Data S4.
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OPEN ACCESS Articleand live virus neutralization assays, respectively. The 0.9 mg
dose of the S-2P trimer and both doses of the monomeric
RBD failed to elicit detectable neutralization activity after two
immunizations. Similar increases in pseudovirus neutralization
were observed after the second immunization in the Darwin
mice, although the titers were lower overall than in BALB/c1374 Cell 183, 1367–1382, November 25, 2020mice (Figure 5F; Data S3). These results are consistent with
the derivation of Darwinmice from the 129S7 and C57BL/6J ge-
netic background (Lee et al., 2014), the latter of which has pre-
viously been shown to generate lower magnitude humoral re-
sponses compared to immunization of BALB/c mice (Corbett
et al., 2020).
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RBD nanoparticles elicit potent neutralizing Ab responses in
two mouse models that exceed those elicited by the prefu-
sion-stabilized S-2P trimer and, after two doses, by infection
in humans. Second, linker length and antigen valency did not
substantially impact the overall immunogenicity of the RBD
nanoparticles, although there is a trend suggesting that RBD-
16GS-I53-50may bemore immunogenic than the nanoparticles
with shorter linkers. These observations are consistent with the
antigenicity and accessibility data presented in Table 1 and Fig-
ure 2 showing that multiple epitopes are intact and accessible in
all RBD nanoparticle immunogens. Finally, the elicitation of
comparable neutralizing Ab titers by both the 0.9 and 5 mg
doses of each nanoparticle immunogen suggests that RBD pre-
sentation on the I53-50 nanoparticle enables dose sparing,
which is a key consideration for vaccine manufacturing and
distribution.
Eight mice immunized with AddaVax only, monomeric RBD,
S-2P trimer, or RBD-8GS- or RBD-12GS- I53-50 nanoparticles
were challenged 7 weeks post-boost with a mouse-adapted
SARS-CoV-2 virus (SARS-CoV-2 MA) to determine whether
these immunogens confer protection from viral replication
(Dinnon et al., 2020a). The RBD-8GS- and RBD-12GS-I53-50
nanoparticles provided complete protection from detectable
SARS-CoV-2 MA replication in mouse lung and nasal turbinates
(Figures 5G and 5H). Immunization with the monomeric RBD,
0.9 mg S-2P trimer, and adjuvant control did not protect from
SARS-CoV-2MA replication. These resultsmirrored our pseudo-
virus and live virus neutralization data showing that the RBD
nanoparticles induce potent anti-SARS-CoV-2 Ab responses at
either dose or valency.
RBD Nanoparticle Vaccines Elicit Robust B Cell
Responses and Abs Targeting Multiple Epitopes in Mice
and a Nonhuman Primate
Germinal center (GC) responses are a key process in the for-
mation of durable B cell memory, resulting in the formation of
affinity-matured, class-switched memory B cells and long-
lived plasma cells. We therefore evaluated the antigen-specific
GC B cell responses in mice immunized with the monomeric
RBD, S-2P trimer, and RBD-8GS-, RBD-12GS-, or RBD-
16GS-I53-50 nanoparticles. The quantity and phenotype of
RBD-specific B cells were assessed 11 days after immuniza-
tion to determine levels of GC precursors and B cells
(B220+CD3–CD138–CD38–GL7+) (Figure S6A). Immunization
with RBD nanoparticles resulted in an expansion of RBD-spe-
cific B cells and GC precursors and B cells (Figures 6A–6C).
The S-2P trimer resulted in a detectable but lower number
and frequency of RBD-specific B cells and GC precursors
and B cells compared to the RBD nanoparticles, whereas
the monomeric RBD did not elicit an appreciable B cell
response. Consistent with these findings, immunization with
the three RBD nanoparticles and trimeric S-2P led to the
emergence of CD38+/–GL7+ IgM+ and class-switched (swIg+)
RBD-specific B cells, indicative of functional GC precursors
and GC B cells (Figure 6D). The robust GC B cell responses
and increased proportions of IgM+ and swIg+ RBD-specific
B cells in the mice immunized with the RBD nanoparticlesand, to a lesser extent, S-2P trimer is consistent with an
ongoing GC reaction, which in time should result in the forma-
tion of memory B cells and long-lived plasma cells. To eval-
uate the durability of humoral responses elicited by the RBD
nanoparticle vaccines, we analyzed serum Ab responses
20–24 weeks post-boost. The magnitude of both binding
and neutralization titers were similar to their levels two weeks
post-boost for all nanoparticle groups (Figures S6B and S6C),
indicating that the designed immunogens elicit not only potent
but also durable neutralizing Abs. This is likely due in part to
improved induction of long-lived plasma cells by the nanopar-
ticle vaccines, as the number of S-2P-specific Ab secreting
cells in the bone marrow was 3-fold higher for mice immu-
nized with the RBD-16GS-I53-50 nanoparticle compared to
the S-2P trimer (Figure S6D).
We compared the ratio of binding to neutralizing Abs eli-
cited by S-2P and the RBD-8GS-, RBD-12GS-, and RBD-
16GS-I53-50 nanoparticles and HCS as a measure of the
quality of the Ab responses elicited by the nanoparticle immu-
nogens (Graham, 2020). In Kymab Darwin mice, the nanopar-
ticle vaccines had lower (better) ratios than S-2P-immunized
mice but higher than HCS (Figure 6E). In BALB/c mice, the ra-
tio of binding to pseudovirus neutralizing titers elicited by
RBD-12GS- and RBD-16GS-I53-50 was clearly decreased
compared to S-2P and HCS (Figure 6F). This pattern was
consistent when ratios were calculated using live virus
neutralizing titers, although the magnitude of the differences
between groups were smaller due to the high values obtained
in the live virus neutralization assay. These results suggest
the Ab responses elicited by the RBD-12GS- and RBD-
16GS-I53-50 nanoparticle immunogens are of higher quality
than that obtained from immunization with the S-2P trimer
or acquired during natural infection, perhaps because it is
focused on epitopes in the RBD that are the target of most
neutralizing Abs (Piccoli et al., 2020).
We set out to identify the epitopes recognized by Abs elicited
upon immunization with the nanoparticle immunogens in a
nonhuman primate model that more closely resembles humans
in their immune response to vaccination. We immunized a pigtail
macaque with 250 mg of RBD-12GS-I53-50 (88 mg of RBD anti-
gen) at weeks 0 and 4 and found that serum collected at week
8 had high levels of S-specific Abs (EC50 13 106) and pseudo-
virus neutralizing Abs (IC50 93 10
2). Polyclonal Fabs were gener-
ated and purified for use in competition BLI with hACE2,
CR3022, and S309, which recognize three distinct sites targeted
by neutralizing Abs on the SARS-CoV-2 RBD (Figure 6G) (Barnes
et al., 2020; Huo et al., 2020; Piccoli et al., 2020; Pinto et al.,
2020; Yuan et al., 2020; Zhou et al., 2020a). The polyclonal
sera inhibited binding of hACE2, CR3022 Fab, and S309 Fab at
concentrations above their respective dissociation constants in
a dose-dependent manner (Figures 6H–6J). These data indicate
that immunization with RBD-12GS-I53-50 elicited Abs targeting
several non-overlapping epitopes, including antigenic sites I, II,
and IV (Piccoli et al., 2020). Although we did not test for compe-
tition with Abs targeting all known neutralizing epitopes, we
expect the multiple Ab specificities elicited by the RBD nanopar-
ticles to limit the potential for emergence and selection of escape
mutants, especially since coronaviruses do not mutate quicklyCell 183, 1367–1382, November 25, 2020 1375
Figure 6. RBD Nanoparticle Vaccines Elicit Robust B Cell Responses and Abs Targeting Multiple Epitopes in Mice and a Nonhuman Primate
(A and B) Number of RBD+ B cells (B220+CD3–CD138–) (A) and RBD+ GC precursors and B cells (CD38+/–GL7+) (B) detected across each immunization group.
(C and D) Frequency of RBD+ GC precursors and B cells (CD38+/–GL7+) (C) and IgD+, IgM+, or class-switched (IgM–IgD–; swIg+) RBD+ GC precursors and
B cells (D).
In (A–D), n = 6 across two experiments for each group. Statistical significance was determined by one-way ANOVA, and Tukey’s multiple comparisons tests were
performed for any group with a p value less than 0.05. Significance is indicated with stars: *p < 0.05; ****p < 0.0001.
(E) Ratio post-boost (week 5) of S-2P ELISA binding titer (Figure 4D) to pseudovirus neutralization titers (Figure 5F) in Kymab Darwin mice. The ratio is the (GMT
[EC50] of five mice):(the GMT [IC50] of five mice) or the EC50:IC50 of all HCS tested. Lower values correspond to higher quality Ab responses.
(F) Ratio post-boost (week 5) of S-2P ELISA binding titer (Figure 4B) to either pseudovirus (Figure 5B) or live virus (Figure 5D) neutralization titers in BALB/c mice.
The ratio is the (GMT [EC50] of 10 mice]:(the GMT [IC50] of 10 mice) or the EC50:IC50 of all HCS tested.
(G) SARS-CoV-2 RBD (gray ribbon) with monomeric ACE2 (blue surface), CR3022 Fab (green surface), and S309 Fab (red surface) bound.
(H–J) Determination of vaccine-elicited Ab epitope specificity by competition BLI. A dilution series of purified polyclonal NHP Fabs was pre-incubated with the
SARS-CoV-2 RBD immobilized on BLI biosensors. The 1:3 dilution series of polyclonal Fabs is represented from dark to light, with a dark gray line representing
competitor loaded to apo-RBD (no competition). Competition with 200 nM ACE2 (H), 400 nM CR3022 (I), or 20 nM S309 (J).
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2020b; Smith et al., 2014).
DISCUSSION
A wide variety of SARS-CoV-2 vaccine candidates spanning
diverse vaccine modalities are currently in preclinical or clinical
development. Multivalent antigen presentation on self-assem-
bling protein scaffolds is being increasingly explored in clinical1376 Cell 183, 1367–1382, November 25, 2020vaccine development, largely due to the availability of robust
platforms that enable the display of complex antigens, including
oligomeric viral glycoproteins (Irvine and Read, 2020; Kanekiyo
et al., 2019a; López-Sagaseta et al., 2015). Such nanoparticle
vaccines often significantly enhance neutralizing Ab responses
compared to traditional subunit vaccines based on non-particu-
late antigens (Kanekiyo et al., 2013; 2015; Marcandalli et al.,
2019). While preclinical and early clinical development of subunit
vaccines is slower than nucleic acid and vector-based vaccines,
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motivate their prioritization in SARS-CoV-2 vaccine develop-
ment efforts. These advantages include the potential to induce
potent neutralizing Ab responses, the ability to use existing
worldwide capacity for manufacturing recombinant proteins,
and an established regulatory track record.
Here, we showed that two-component self-assembling
SARS-CoV-2 RBD nanoparticle vaccine candidates elicit
potent neutralizing Ab responses targeting multiple distinct
RBD epitopes. Although comparing vaccine candidates
across studies from different groups is complicated by varia-
tions in serological assays, experimental design, and many
other factors, the greater neutralizing Ab responses elicited
by the RBD nanoparticles compared to the prefusion-stabi-
lized S ectodomain trimer are very promising. One of the few
other studies that benchmarked vaccine immunogenicity
against the S-2P trimer delivered as recombinant protein
was a recent preclinical evaluation of mRNA-1273 in mice
(Corbett et al., 2020). At the highest dose tested (1 mg), two
immunizations with mRNA-1273 elicited comparable levels of
S-specific Abs to two immunizations with 1 mg of S-2P trimer
formulated in an adjuvant containing a TLR4 agonist. Addi-
tional reports of potent neutralizing activity obtained by immu-
nization with prefusion-stabilized S(2P) ectodomain (Mando-
lesi et al., 2020) and full-length trimers (Keech et al., 2020)
formulated with powerful adjuvants provide promising data
on the immunogenicity of vaccine candidates based on re-
combinant S proteins. Our data indicate that RBD-12GS-I53-
50 and RBD-16GS-I53-50 elicit nearly 10-fold higher levels
of S-specific Abs and, more importantly, roughly 10-fold
higher levels of neutralizing activity compared to the S-2P ec-
todomain trimer. This enhancement in potency is maintained
at a more than 5-fold lower antigen dose by mass, suggesting
that presentation on the nanoparticle also has a dose-sparing
effect. Both enhanced potency and dose-sparing could be
critical for addressing the need to manufacture an unprece-
dented number of doses of vaccine to respond to the
COVID-19 pandemic.
Several recent studies have indicated that the RBD is the
target of most neutralizing activity in COVID-19 HCS (Barnes
et al., 2020; Brouwer et al., 2020; Piccoli et al., 2020;
Pinto et al., 2020; Robbiani et al., 2020; Seydoux et al., 2020;
Wang et al., 2020a; Wu et al., 2020). Although the RBD is poorly
immunogenic as a monomer, our data establish that it can form
the basis of a highly immunogenic vaccine when presented
multivalently. This conclusion is consistent with a recent report
of dimerization increasing the immunogenicity of the RBD from
several coronavirus S proteins, including SARS-CoV-2 S (Dai
et al., 2020), as well as a nanoparticle vaccine candidate for
Epstein-Barr virus conceptually similar to our RBD nanoparticle
immunogens that displayed the CR2-binding domain of gp350
(Kanekiyo et al., 2015). The exceptionally low binding:neutraliz-
ing ratio elicited upon immunization with the RBD nanoparticles
suggests that presentation of the RBD on I53-50 focuses the
humoral response on epitopes recognized by neutralizing
Abs. This metric has been identified as a potentially important
indicator of vaccine safety, as high levels of binding yet non-
neutralizing or weakly neutralizing Abs may contribute to vac-cine-associated enhancement of respiratory disease (Graham,
2020; Kim et al., 1969; Polack et al., 2002). Our data further
show that RBD-12GS-I53-50 elicited Ab responses targeting
several of the non-overlapping RBD antigenic sites recognized
by neutralizing Abs (Piccoli et al., 2020). As several naturally
occurring RBD mutations identified among circulating SARS-
CoV-2 isolates were shown to abrogate interactions with
known monoclonal Abs and to reduce immune sera binding
(Li et al., 2020a), formulation of potent Ab cocktails was pro-
posed to overcome immune evasion (Baum et al., 2020; Han-
sen et al., 2020; Tortorici et al., 2020). Accordingly, the diverse
polyclonal Ab responses elicited by the RBD-12GS-I53-50
nanoparticle, targeting multiple distinct epitopes, might explain
the magnitude of neutralization observed and should minimize
the risk of selection or emergence of escape mutations (Davis
et al., 2018; Lee et al., 2019). Finally, the high production yield
of RBD-I53-50A components and the robust stability of the an-
tigen-bearing RBD nanoparticles suggests that these will likely
be more amenable to large-scale manufacturing than the
SARS-CoV-2 S-2P trimer, which expresses poorly and is unsta-
ble (Edwards et al., 2020; Hsieh et al., 2020; McCallum
et al., 2020).
The emergence of three highly pathogenic zoonotic corona-
viruses in the past two decades showcases that vaccines
capable of providing broad protection against coronaviruses
are urgently needed for future pandemic preparedness. As vi-
ruses similar to SARS-CoV (Menachery et al., 2015), MERS-
CoV (Anthony et al., 2017; Woo et al., 2006), and SARS-
CoV-2 (Zhou et al., 2020b; 2020c) have been found in animal
reservoirs, the potential for the emergence of similar viruses
in the future poses a significant threat to global public health.
The RBD nanoparticle vaccines described here are not ex-
pected to provide protection against distantly related corona-
viruses (e.g., MERS-CoV) due to substantial sequence varia-
tion among the RBDs of coronavirus S glycoproteins.
However, the potent neutralizing Ab responses elicited by
the nanoparticle immunogens combined with recent work
demonstrating that co-displaying multiple antigens on the
same nanoparticle can improve the breadth of vaccine-eli-
cited immune responses (Boyoglu-Barnum et al., 2020; Kane-
kiyo et al., 2019b) suggests a potential route to broader coro-
navirus vaccines. Alternatively, optimizing the expression,
stability, and multivalent display of prefusion S ectodomain
trimers may lead to elicitation of even broader Ab responses
based on the greater sequence and structural conservation of
the S2 subunit (i.e., the fusion machinery) among coronavi-
ruses (Walls et al., 2016a; 2020) and the fact that it contains
conserved epitopes that are targeted by neutralizing Abs
such as the fusion peptide (Poh et al., 2020). Several reports
of stabilized prefusion SARS-CoV-2 S variants provide prom-
ising antigens that can be used to test this hypothesis (Hen-
derson et al., 2020; Hsieh et al., 2020; McCallum et al.,
2020; Xiong et al., 2020). Although a single approach may
be enough for generating protective responses against multi-
ple closely related coronaviruses (e.g., sarbecoviruses), the
genetic diversity across lineages and genera will
likely necessitate a combination of several vaccine design
approaches.Cell 183, 1367–1382, November 25, 2020 1377
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tionally designed two-component nanoparticles to rapidly
generate promising SARS-CoV-2 vaccine candidates that are
highly differentiated frommany other candidates under develop-
ment. Our results add another class I fusion protein to the
growing list of antigens whose immunogenicity is enhanced
through multivalent presentation on two-component nanopar-
ticles. Continued development of such technology platforms
could lead to vaccines that prevent the next pandemic rather
than respond to it (Kanekiyo et al., 2019a; Kanekiyo andGraham,
2020).STAR+METHODS
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Data and Code Availability
All data supporting the findings of this study are found within the paper and its Supplementary Information, and are available from the
Lead Contact author upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
HEK293F is a female human embryonic kidney cell line transformed and adapted to grow in suspension (Life Technologies). HEK293F
cells were grown in 293FreeStyle expression medium (Life Technologies), cultured at 37C with 8% CO2 and shaking at 130 rpm.
Expi293F cells are derived from the HEK293F cell line (Life Technologies). Expi293F cells were grown in Expi293 ExpressionMedium
(Life Technologies), cultured at 36.5C with 8% CO2 and shaking at 150 rpm. VeroE6 is a female kidney epithelial cell from African
green monkey. HEK293T/17 is a female human embryonic kidney cell line (ATCC). The HEK-ACE2 adherent cell line was obtained
through BEI Resources, NIAID, NIH: Human Embryonic Kidney Cells (HEK293T) Expressing Human Angiotensin-Converting
Enzyme 2, HEK293T-hACE2 Cell Line, NR-52511. All adherent cells were cultured at 37C with 8% CO2 in flasks with DMEM +
10% FBS (Hyclone) + 1% penicillin-streptomycin. Cell lines other than Expi293F were not tested for mycoplasma contamination
nor authenticated.
Mice
Female BALB/c mice four weeks old were obtained from Jackson Laboratory, Bar Harbor, Maine. Animal procedures were
performed under the approvals of the Institutional Animal Care and Use Committee of University of Washington, Seattle, WA, and
University of North Carolina, Chapel Hill, NC. Kymab’s proprietary IntelliSelectTM Transgenic mouse platform, known as Darwin,
has complete human antibody loci with a non-rearranged human antibody variable and constant germline repertoire. Consequently,
the antibodies produced by these mice are fully human.
Pigtail macaques
Two adult male Pigtail macaques (Macaca nemestrina) were immunized in this study. All animals were housed at the Washington
National Primate Research Center (WaNPRC), an AAALAC International accredited institution. All experiments were approved by
The University of Washington’s Institutional Animal Care and Use Committee (IACUC). Animals were singly housed in comfortable,
clean, adequately-sized cages with ambient temperatures between 72–82F. Animals received environmental enrichment for the
duration of the study including grooming contact, perches, toys, foraging experiences and access to additional environment enrich-
ment devices. Water was available through automatic watering devices and animals were fed a commercial monkey chow, supple-
mented daily with fruits and vegetables. Throughout the study, animals were checked twice daily by husbandry staff.
Convalescent human sera
Samples collected between 1–60 days post infection from 31 individuals who tested positive for SARS-CoV-2 by PCR were profiled
for anti-SARS-CoV-2 S antibody responses and the 29 with anti-S Ab responses were maintained in the cohort (Figures 4 and 5).
Individuals were enrolled as part of the HAARVI study at the University of Washington in Seattle, WA. Baseline sociodemographic
and clinical data for these individuals are summarized in Data S5. This study was approved by the University of Washington Human
Subjects Division Institutional Review Board (STUDY00000959 and STUDY00003376). All experiments were performed in at least
two technical and two biological replicates (for ELISA and pseudovirus neutralization assays). One sample is the 20/130 COVID-
19 plasma from NIBSC (https://www.nibsc.org/documents/ifu/20-130.pdf).
METHOD DETAILS
Plasmid construction
The SARS-CoV-2 RBD (BEI NR-52422) construct was synthesized byGenScript into pcDNA3.1- with an N-terminal mu-phosphatase
signal peptide and a C-terminal octa-histidine tag (GHHHHHHHH). The boundaries of the construct are N-328RFPN331 and
528KKST531-C (Walls et al., 2020). The SARS-CoV-2 S-2P ectodomain trimer (GenBank: YP_009724390.1, BEI NR-52420) was
synthesized by GenScript into pCMV with an N-terminal mu-phosphatase signal peptide and a C-terminal TEV cleavage site
(GSGRENLYPQG), T4 fibritin foldon (GGGSGYIPEAPRDGQAYVRKDGEWVLLSTPL), and octa-histidine tag (GHHHHHHHH) (Walls
et al., 2020). The construct contains the 2P mutations (proline substitutions at residues 986 and 987; (Pallesen et al., 2017)) and
an 682SGAG685 substitution at the furin cleavage site. The SARS-CoV-2 RBD was genetically fused to the N terminus of the
trimeric I53-50A nanoparticle component using linkers of 8, 12, or 16 glycine and serine residues. RBD-8GS- and RBD-12GS-I53-
50A fusions were synthesized and cloned by Genscript into pCMV. The RBD-16GS-I53-50A fusion was cloned into pCMV/R using
the Xba1 and AvrII restriction sites and Gibson assembly (Gibson et al., 2009). All RBD-bearing components contained an N-terminalCell 183, 1367–1382.e1–e10, November 25, 2020 e3
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to a sequence encoding a thrombin cleavage site and a human Fc fragment at the C-terminal end. hACE2-Fc was synthesized and
cloned by GenScript with a BM40 signal peptide. Plasmids were transformed into the NEB 5-alpha strain of E. coli (New England
Biolabs) for subsequent DNA extraction from bacterial culture (NucleoBond Xtra Midi kit) to obtain plasmid for transient transfection
into Expi293F cells. The amino acid sequences of all novel proteins used in this study can be found in Data S1.
Transient transfection
SARS-CoV-2 S and ACE2-Fc proteins were produced in Expi293F cells grown in suspension using Expi293F expression medium
(Life Technologies) at 33C, 70% humidity, 8% CO2 rotating at 150 rpm. The cultures were transfected using PEI-MAX (Polyscience)
with cells grown to a density of 3.0 million cells per mL and cultivated for 3 days. Supernatants were clarified by centrifugation (5 min
at 4000 rcf), addition of PDADMAC solution to a final concentration of 0.0375% (Sigma Aldrich, #409014), and a second spin (5 min at
4000 rcf).
Genes encoding CR3022 heavy and light chains were ordered from GenScript and cloned into pCMV/R. Antibodies were
expressed by transient co-transfection of both heavy and light chain plasmids in Expi293F cells using PEI MAX (Polyscience)
transfection reagent. Cell supernatants were harvested and clarified after 3 or 6 days as described above.
Protein purification
ProteinscontainingHis tagswerepurified fromclarifiedsupernatants via abatchbindmethodwhereeachclarifiedsupernatantwas sup-
plemented with 1 M Tris-HCl pH 8.0 to a final concentration of 45 mM and 5 M NaCl to a final concentration of310 mM. Talon cobalt
affinity resin (Takara) was added to the treated supernatants and allowed to incubate for 15minwith gentle shaking. Resinwas collected
using vacuum filtration with a 0.2 mm filter and transferred to a gravity column. The resin was washed with 20 mM Tris pH 8.0, 300 mM
NaCl, and the proteinwas elutedwith 3 columnvolumesof 20mMTrispH8.0, 300mMNaCl, 300mM imidazole. The batch bindprocess
was then repeatedand the first andsecondelutions combined.SDS-PAGEwasused toassesspurity. RBD-I53-50A fusionprotein IMAC
elutionswereconcentrated to>1mg/mLand subjected to three roundsofdialysis into50mMTrispH7, 185mMNaCl, 100mMArginine,
4.5% glycerol, and 0.75% w/v 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) in a hydrated 10K molecular
weight cutoff dialysis cassette (ThermoScientific). S-2P IMACelution fractionswereconcentrated to1mg/mLanddialyzed three times
into 50mM Tris pH 8, 150 mMNaCl, 0.25% L-Histidine in a hydrated 10Kmolecular weight cutoff dialysis cassette (Thermo Scientific).
Due to inherent instability, the S-2P trimer was immediately flash frozen and stored at 80C.
Clarified supernatants of cells expressing monoclonal antibodies and human or macaque ACE2-Fc were purified using a
MabSelect PrismA 2.63 5 cm column (Cytiva) on an AKTA Avant150 FPLC (Cytiva). Bound antibodies were washed with five column
volumes of 20 mM NaPO4, 150 mM NaCl pH 7.2, then five column volumes of 20 mM NaPO4, 1 M NaCl pH 7.4 and eluted with three
column volumes of 100 mM glycine at pH 3.0. The eluate was neutralized with 2 M Trizma base to 50 mM final concentration. SDS-
PAGE was used to assess purity.
Recombinant S309 was expressed as a Fab in expiCHO cells transiently co-transfected with plasmids expressing the heavy and
light chain, as described above (see Transient transfection) (Stettler et al., 2016). The protein was affinity-purified using a HiTrap
Protein A Mab select Xtra column (Cytiva) followed by desalting against 20 mM NaPO4, 150 mM NaCl pH 7.2 using a HiTrap Fast
desalting column (Cytiva). The protein was sterilized with a 0.22 mm filter and stored at 4C until use.
Microbial protein expression and purification
The I53-50A and I53-50B.4.PT1 proteins were expressed in Lemo21(DE3) (NEB) in LB (10 g Tryptone, 5 g Yeast Extract, 10 g NaCl)
grown in 2 L baffled shake flasks or a 10 L BioFlo 320 Fermenter (Eppendorf). Cells were grown at 37C to an OD600 0.8, and then
induced with 1mM IPTG. Expression temperature was reduced to 18C and the cells shaken for16 h. The cells were harvested and
lysed by microfluidization using a Microfluidics M110P at 18,000 psi in 50 mM Tris, 500 mM NaCl, 30 mM imidazole, 1 mM PMSF,
0.75%CHAPS. Lysates were clarified by centrifugation at 24,000 g for 30min and applied to a 2.63 10 cmNi Sepharose 6 FF column
(Cytiva) for purification by IMAC on an AKTA Avant150 FPLC system (Cytiva). Protein of interest was eluted over a linear gradient of
30 mM to 500 mM imidazole in a background of 50 mM Tris pH 8, 500 mM NaCl, 0.75% CHAPS buffer. Peak fractions were pooled,
concentrated in 10K MWCO centrifugal filters (Millipore), sterile filtered (0.22 mm) and applied to either a Superdex 200 Increase
10/300, or HiLoad S200 pg GL SEC column (Cytiva) using 50 mM Tris pH 8, 500 mM NaCl, 0.75% CHAPS buffer. I53-50A elutes
at 0.6 column volume (CV). I53-50B.4PT1 elutes at 0.45 CV. After sizing, bacterial-derived components were tested to confirm
low levels of endotoxin before using for nanoparticle assembly.
In vitro nanoparticle assembly
Total protein concentration of purified individual nanoparticle components was determined by measuring absorbance at 280 nm
using a UV/vis spectrophotometer (Agilent Cary 8454) and calculated extinction coefficients (Gasteiger et al., 2005). The assembly
steps were performed at room temperature with addition in the following order: RBD-I53-50A trimeric fusion protein, followed by
additional buffer as needed to achieve desired final concentration, and finally I53-50B.4PT1 pentameric component (in 50 mM
Tris pH 8, 500 mM NaCl, 0.75% w/v CHAPS), with a molar ratio of RBD-I53-50A:I53-B.4PT1 of 1.1:1. In order to produce partial
valency RBD-I53-50 nanoparticles (50% RBD-I53-50), both RBD-I53-50A and unmodified I53-50A trimers (in 50 mM Tris pH 8,e4 Cell 183, 1367–1382.e1–e10, November 25, 2020
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were incubated at 2-8C with gentle rocking for at least 30 min before subsequent purification by SEC in order to remove residual
unassembled component. Different columns were utilized depending on purpose: Superose 6 Increase 10/300 GL column was
used analytically for nanoparticle size estimation, a Superdex 200 Increase 10/300 GL column used for small-scale pilot assemblies,
and a HiLoad 26/600 Superdex 200 pg column used for nanoparticle production. Assembled particles elute at11mL on the Super-
ose 6 column and in the void volume of Superdex 200 columns. Assembled nanoparticles were sterile filtered (0.22 mm) immediately
prior to column application and following pooling of fractions.
hACE2-Fc and CR3022 digestion
hACE2-Fc was digested with thrombin protease (Sigma Aldrich) in the presence of 2.5 mM CaCl2 at a 1:300 w/w thrombin:protein
ratio. The reaction was incubated at ambient temperature for 16–18 h with gentle rocking. Following incubation, the reaction mixture
was concentrated using Ultracel 10K centrifugal filters (Millipore Amicon Ultra) and sterile filtered (0.22 mM). Cleaved hACE2 mono-
mer was separated from uncleaved hACE2-Fc and the cleaved Fc regions using Protein A purification (see Protein purification above)
on a HiScreen MabSelect SuRe column (Cytiva) using an ӒKTA avant 25 FPLC (Cytiva). Cleaved hACE2 monomer was collected in
the flow through, sterile filtered (0.22 mm), and quantified by UV/vis.
LysC (New England BioLabs) was diluted to 10 ng/mL in 10 mM Tris pH 8 and added to CR3022 IgG at 1:2000 w/w LysC:IgG and
subsequently incubated for 18 h at 37Cwith orbital shaking at 230 rpm. The cleavage reaction was concentrated using Ultracel 10K
centrifugal filters (Millipore Amicon Ultra) and sterile filtered (0.22 mM). Cleaved CR3022mAbwas separated from uncleaved CR3022
IgG and the Fc portion of cleaved IgG, using Protein A purification as described above. Cleaved CR3022 was collected in the flow
through, sterile filtered (0.22 mm), and quantified by UV/vis.
Bio-layer interferometry (antigenicity)
Antigenicity assays were performed and analyzed using BLI on an Octet Red 96 System (Pall Forté Bio/Sartorius) at ambient tem-
perature with shaking at 1000 rpm. RBD-I53-50A trimeric components and monomeric RBD were diluted to 40 mg/mL in Kinetics
buffer (1 3 HEPES-EP+ (Pall Forté Bio), 0.05% nonfat milk, and 0.02% sodium azide). Monomeric hACE2 and CR3022 Fab were
diluted to 750 nM in Kinetics buffer and serially diluted three-fold for a final concentration of 3.1 nM. Reagents were applied to a black
96-well Greiner Bio-one microplate at 200 mL per well as described below. RBD-I53-50A components or monomeric RBD were
immobilized onto Anti-Penta-HIS (HIS1K) biosensors per manufacturer instructions (Forté Bio) except using the following sensor in-
cubation times. HIS1K biosensors were hydrated in water for 10min, andwere then equilibrated in Kinetics buffer for 60 s. The HIS1K
tips were loaded with diluted trimeric RBD-I53-50A component or monomeric RBD for 150 s and washed with Kinetics buffer for 300
s. The association step was performed by dipping the HIS1K biosensors with immobilized immunogen into diluted hACE2 monomer
or CR3022 Fab for 600 s, then dissociation was measured by inserting the biosensors back into Kinetics buffer for 600 s. The data
were baseline subtracted and the plots fitted using the Pall FortéBio/Sartorius analysis software (version 12.0). Plots in Figure S2
show the association and dissociation steps.
Bio-layer interferometry (accessibility)
Binding of mACE2-Fc, CR3022 IgG, and S309 IgG to monomeric RBD, RBD-I53-50A trimers, and RBD-I53-50 nanoparticles was
analyzed for accessibility experiments and real-time stability studies using an Octet Red 96 System (Pall FortéBio/Sartorius) at
ambient temperature with shaking at 1000 rpm. Protein samples were diluted to 100 nM in Kinetics buffer. Buffer, immunogen,
and analyte were then applied to a black 96-well Greiner Bio-onemicroplate at 200 mL per well. Protein A biosensors (FortéBio/Sarto-
rius) were first hydrated for 10 min in Kinetics buffer, then dipped into either mACE2-Fc, CR3022, or S309 IgG diluted to 10 mg/mL in
Kinetics buffer in the immobilization step. After 500 s, the tips were transferred to Kinetics buffer for 60 s to reach a baseline. The
association step was performed by dipping the loaded biosensors into the immunogens for 300 s, and subsequent dissociation
was performed by dipping the biosensors back into Kinetics buffer for an additional 300 s. The data were baseline subtracted prior
to plotting using the FortéBio analysis software (version 12.0). Plots in Figure 2 show the 600 s of association and dissociation.
Negative stain electron microscopy
RBD-I53-50 nanoparticles were first diluted to 75 mg/mL in 50 mM Tris pH 7, 185 mM NaCl, 100 mM Arginine, 4.5% v/v Glycerol,
0.75%w/v CHAPS, and S-2P protein was diluted to 0.03 mg/mL in 50 mM Tris pH 8, 150 mM NaCl, 0.25% L-Histidine prior to appli-
cation of 3 mL of sample onto freshly glow-discharged 300-mesh copper grids. Sample was incubated on the grid for 1min before the
grid was dipped in a 50 mL droplet of water and excess liquid blotted away with filter paper (Whatman). The grids were then dipped
into 6 mL of 0.75%w/v uranyl formate stain. Stain was blotted off with filter paper, then the grids were dipped into another 6 mL of stain
and incubated for70 s. Finally, the stain was blotted away and the grids were allowed to dry for 1 min. Prepared grids were imaged
in a Talos model L120C electron microscope at 45,000 3 (nanoparticles) or 92,000 3 magnification (S-2P).
Dynamic light scattering
Dynamic Light Scattering (DLS) was used to measure hydrodynamic diameter (Dh) and%Polydispersity (%Pd) of RBD-I53-50 nano-
particle samples on an UNcle Nano-DSF (UNchained Laboratories). Sample was applied to a 8.8 mL quartz capillary cassette (UNi,Cell 183, 1367–1382.e1–e10, November 25, 2020 e5
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to 4.5% v/v glycerol in the RBD nanoparticle buffer was accounted for by the UNcle Client software in Dh measurements.
Guanidine HCl denaturation
Monomeric RBD, RBD-I53-50A fusion proteins, and RBD-I53-50 nanoparticle immunogens were diluted to 2.5 mM in 50 mM Tris pH
7.0, 185 mMNaCl, 100mMArginine, 4.5% v/v glycerol, 0.75%w/v CHAPS, and guanidine chloride [GdnHCl] ranging from 0M to 6.5
M, increasing in 0.25M increments, and prepared in triplicate. S-2P trimer was also diluted to 2.5 mMusing 50mM Tris pH 8, 150mM
NaCl, 0.25% L-Histidine, and the same GuHCl concentration range. Dilutions were mixed 103 by pipetting. The samples were then
incubated 18–19 h at ambient temperature. Using a Nano-DSF (UNcle, UNchained Laboratories) and an 8.8 mL quartz capillary
cassette (UNi, UNchained Laboratories), fluorescence spectra were collected in triplicate, exciting at 266 nm and measuring
emission from 200 nm to 750 nm at 25C.
Endotoxin measurements
Endotoxin levels in protein samples were measured using the EndoSafe Nexgen-MCS System (Charles River). Samples were diluted
1:50 or 1:100 in Endotoxin-free LAL reagent water, and applied into wells of an EndoSafe LAL reagent cartridge. Charles River
EndoScan-V software was used to analyze endotoxin content, automatically back-calculating for the dilution factor. Endotoxin
values were reported as EU/mL which were then converted to EU/mg based on UV/vis measurements. Our threshold for samples
suitable for immunization was < 50 EU/mg.
UV/vis
Ultraviolet-visible spectrophotometry (UV/vis) was measured using an Agilent Technologies Cary 8454. Samples were applied to a
10 mm, 50 mL quartz cell (Starna Cells, Inc.) and absorbance was measured from 180 to 1000 nm. Net absorbance at 280 nm,
obtained from measurement and single reference wavelength baseline subtraction, was used with calculated extinction coefficients
and molecular weights to obtain protein concentration. The ratio of absorbance at 320/280 nm was used to determine relative
aggregation levels in real-time stability study samples. Samples were diluted with respective purification/instrument blanking buffers
to obtain an absorbance between 0.1 and 1.0. All data produced from the UV/vis instrument was processed in the 845x UV/visible
System software.
Glycan profiling
To identify site-specific glycosylation profiles, including glycoform distribution and occupancy determination, a bottom up mass
spectrometry (MS) approach was utilized. Aliquots of 1 mg/mL monomeric, 8GS, 12GS and 16GS RBD protein were prepared to
evaluate the glycosylation profiles at N331 and N343 of the four RBD variants. Comprehensive glycoprofiling on the stabilized Spike
ectodomain (S-2P) was performed in parallel using 1.5 mg/mL SARS-CoV-2 S-2P protein. All the samples were denatured in a so-
lution containing 25mM Tris (pH 8.0), 7 M guanidinium chloride (GdnHCl) and 50mMdithiothreitol (DTT) at 90C for 30 min. Reduced
cysteines were alkylated by adding fresh iodoacetamide (IAA) to 100 mM and incubating at room temperature for 1 h in the dark.
50 mM excess DTT was then added to quench the remaining IAA. The GndHCl concentration was reduced to 0.6 M by diluting
the samples 11-fold with a 10 mM Tris (pH 8.0), 2 mM calcium chloride solution. Each sample was then split in half. One half
(275 mL) was mixed with 10 units of recombinant Peptide N-glycanase F (GST-PNGase F) (Krenkova et al., 2013) and incubated
at 37C for 1 h in order to convert glycosylated Asn into deglycosylated Asp.
Protease digestions were performed in the followingmanner: all RBD samples and one S-2P sample were digested with Lys-C at a
ratio of 1:40 (w/w) for RBD and 1:30 (w/w) for S-2P for 4 h at 37C, followed by Glu-C digestion overnight at the same ratios and con-
ditions. The other three S-2P samples were digested with trypsin, chymotrypsin and alpha lytic protease, respectively, at a ratio of
1:30 (w/w) overnight at 37C. All the digestion proteases used were MS grade (Promega). The next day, the digestion reactions were
quenched by 0.02% formic acid (FA, OptimaTM, Fisher).
The glycoform determination of four S-2P samples was performed by nano LC-MS using an Orbitrap FusionTMmass spectrometer
(Thermo Fisher). The digested samples were desalted by Sep-Pak C18 cartridges (Waters) following the manufacturer’s suggested
protocol. A 2 cm trapping column and a 35 cm analytical columnwere freshly prepared in fused silica (100 mm ID) with 5 mMReproSil-
Pur C18 AQbeads (Dr.Maisch). 8 mL sample was injected and run by a 60-min linear gradient from 2% to 30%acetonitrile in 0.1%FA,
followed by 10min of 80% acetonitrile. An EThcDmethod was optimized as followed: ion source: 2.1 kV for positive mode; ion trans-
fer tube temperature: 350 þC; resolution: MS1 = 120000, MS2 = 30000; AGC target: MS1 = 2e5, MS2 = 1e5; and injection time: MS1 =
50 ms, MS2 = 60 ms.
Glycopeptide data were visualized and processed by ByonicTM and ByologicTM (Version 3.8, Protein Metrics Inc.) using a 6 ppm
precursor and 10 ppm fragment mass tolerance. Glycopeptides were searched using the N-glycan 309mammalian database in Pro-
tein Metrics PMI-Suite and scored based on the assignment of correct c- and z- fragment ions. The true-positive entities were further
validated by the presence of glycan oxonium ions m/z at 204 (HexNAc ions) and 366 (HexNAcHex ions) and the absence in its cor-
responding spectrum in the deglycosylated sample. The relative abundance of each glycoform was determined by the peak area
analyzed in ByologicTM. Glycoforms were categorized as either Oligomannose: HexNAc(2)Hex(9-5); Hybrid: HexNAc(3)Hex(5-6);
or various subtypes of Complex: HexNAc(3)Hex(3-4)X as A1 subtype; HexNAc(4)X as A2/A1B; HexNAc(5)X as A3/A2B; ande6 Cell 183, 1367–1382.e1–e10, November 25, 2020
ll
OPEN ACCESSArticleHexNAc(6)X as A4/A3B subtype. Hybrid and Complex forms with fucosylation are separately listed as FHybrid and FComplex (e.g.,
FA1), respectively (Watanabe et al., 2020).
Glycan occupancy analysis and glycoform determination of the four RBD variants were performed by LC-MS on the Synapt
G2-SiTM TOF mass spectrometer coupled to an Acquity UPLC system (Waters). Samples were resolved over a Waters CSH C18
1 3 100 mm 1.7 mm column with a linear gradient from 3% to 40% B over 30 min (A: 98% water, 2% acetonitrile, 0.1% FA; B:
100% acetonitrile, 0.1% FA). Data dependent acquisition (DDA) method was utilized with precursor mass range 300-2000,
MS/MS mass range 50-2000 and a collision energy ramped from 70 to 100 V. Chromatographic peaks for the most abundant and
non-overlapped isotopic peaks were determined and integrated with MassLynx (Waters). All the water and organic solvents used,
unless specifically stated, wereMS grade (OptimaTM, Fisher). The peak area ratio of the non-glycosylated (Asn) to the deglycosylated
(Asp) glycopeptide was used to measure the glycan occupancy at each site.
Hydrogen/Deuterium-exchange mass spectrometry
3 mg of monomeric RBD and RBD-8GS-I53-50A were incubated and H/D exchanged (HDX) in the deuteration buffer (pH* 7.6, 85%
D2O, Cambridge Isotope Laboratories, Inc.) for 3, 60, 1800, and 72000 s, respectively, at 23
C. Samples were subsequently mixed
1:1 with ice-cold quench buffer (200 mM tris(2-chlorethyl) phosphate (TCEP), 8 M Urea, 0.2% formic acid) for a final pH 2.5 and
immediately flash frozen in liquid nitrogen. Samples were analyzed by LC-MS on a Synapt G2-Si mass spectrometer using a custom
built cooling box to maintain all columns, loops, valves, and lines at 0C. Quenched samples were loaded over a custom packed
immobilized pepsin column (2.1 3 50 mm) with a flow of 0.1% trifluoroacetic acid with 2% acetonitrile at 200 mL/min. Peptides
were trapped on a Waters CSH C18 trap cartridge (2.1 3 5 mm) and resolved over a Waters CSH C18 1 3 100 mm 1.7 mm column
with a linear gradient from 3% to 40% B over 18 min (A: 98% water, 2% acetonitrile, 0.1% FA, 0.025% trifluoroacetic acid; B: 100%
acetonitrile, 0.1% FA, flow rate of 40 mL/min). A series of washes steps were performed between all samples to minimize carryover
(Verkerke et al., 2016). A fully deuteration control was made by collecting the pepsin digest eluate from an undeuterated sample
LC-MS run, drying by speedvac, incubating in deuteration buffer for 1 h at 85C, and quenching the same as all other HDX samples.
Internal exchange standards (Pro-Pro-Pro-Ile [PPPI] and Pro-Pro-Pro-Phe [PPPF]) were added in each sample to ensure consistent
labeling conditions for all samples (Zhang et al., 2012). Pepsin digests for undeuterated samples were also analyzed by nano LC-MS
using an Orbitrap FusionTMmass spectrometer (Thermo Fisher) with the settings as described above for glycoprofiling. The data was
then processed by ByonicTM to obtain the peptide reference list. Peptides were manually validated using DriftScopeTM (Waters) and
identified with orthogonal retention time (rt) and drift time (dt) coordinates. Deuterium uptake analysis was performed with HX-Ex-
press v2 (Guttman et al., 2013; Weis et al., 2006). Peaks were identified from the peptide spectra with binomial fitting applied.
The deuterium uptake level was normalized relative to fully deuterated standards.
Mouse immunizations and challenge
Female BALB/c (Stock: 000651) micewere purchased at the age of four weeks from The Jackson Laboratory, Bar Harbor, Maine, and
maintained at the Comparative Medicine Facility at the University of Washington, Seattle, WA, accredited by the American Associ-
ation for the Accreditation of Laboratory Animal Care International (AAALAC). At six weeks of age, 10 mice per dosing group were
vaccinated with a prime immunization, and three weeks later mice were boosted with a second vaccination. Prior to inoculation,
immunogen suspensions were gently mixed 1:1 vol/vol with AddaVax adjuvant (Invivogen, San Diego, CA) to reach a final concen-
tration of 0.009 or 0.05 mg/mL antigen. Mice were injected intramuscularly into the gastrocnemius muscle of each hind leg using a
27-gauge needle (BD, San Diego, CA) with 50 mL per injection site (100 mL total) of immunogen under isoflurane anesthesia. To obtain
sera all mice were bled two weeks after prime and boost immunizations. Blood was collected via submental venous puncture and
rested in 1.5 mL plastic Eppendorf tubes at room temperature for 30 min to allow for coagulation. Serum was separated from
hematocrit via centrifugation at 2,000 g for 10 min. Complement factors and pathogens in isolated serum were heat-inactivated
via incubation at 56C for 60 min. Serum was stored at 4C or 80C until use. Six weeks post-boost, mice were exported from
Comparative Medicine Facility at the University of Washington, Seattle, WA to an AAALAC accredited Animal Biosafety Level 3
(ABSL3) Laboratory at the University of North Carolina, Chapel Hill. After a 7-day acclimation time, mice were anesthetized with a
mixture of ketamine/xylazine and challenged intranasally with 105 plaque-forming units (pfu) of mouse-adapted SARS-CoV-2 MA
strain for the evaluation of vaccine efficacy (IACUC protocol 20-114.0). After infection, body weight was monitored daily until the
termination of the study two days post-infection, when lung and nasal turbinate tissues were harvested to evaluate the viral load
by plaque assay. All experiments were conducted at the University of Washington, Seattle, WA, and University of North Carolina,
Chapel Hill, NC according to approved Institutional Animal Care and Use Committee protocols.
Immunization (Kymab Darwin mice)
Kymab Darwin mice (a mix of males and females, 10 weeks of age), 5 mice per dosing group, were vaccinated with a prime immu-
nization and three weeks later boosted with a second vaccination. Prior to inoculation, immunogen suspensions were gently mixed
1:1 vol/vol with AddaVax adjuvant (Invivogen) to reach a final concentration of 0.009 or 0.05 mg/mL antigen. Mice were injected intra-
muscularly into the tibialis muscle of each hind leg using a 30-gauge needle (BD) with 20 mL per injection site (40 mL total) of immu-
nogen under isoflurane anesthesia. A final boost was administered intravenously (50 uL) with no adjuvant at week 7. Mice were sacri-
ficed 5 days later under UK Home Office Schedule 1 (rising concentration of CO2) and spleen, lymph nodes, and bone marrowCell 183, 1367–1382.e1–e10, November 25, 2020 e7
ll
OPEN ACCESS Articlecryopreserved. Whole blood (0.1 ml) was collected 2 weeks after each dose (weeks 0, 2, 5, and week 8 terminal bleed). Serum was
separated from hematocrit via centrifugation at 2000 g for 10 min. Serum was stored at 20C and was used to monitor titers by
ELISA. All mice were maintained and all procedures carried out under United Kingdom Home Office License 70/8718 and with
the approval of the Wellcome Trust Sanger Institute Animal Welfare and Ethical Review Body.
ELISA
For anti-S-2P ELISA, 25 mL of 2 mg/mL S-2P was plated onto 384-well Nunc Maxisorp (ThermoFisher) plates in PBS and sealed over-
night at 4C. The next day plates were washed 43 in Tris Buffered Saline Tween (TBST) using a plate washer (BioTek) and blocked
with 2% BSA in TBST for 1 h at 37C. Plates were washed 4 3 in TBST and 1:5 serial dilutions of mouse, NHP, or human sera were
made in 25 mL TBST starting at 1:25 or 1:50 and incubated at 37C for 1 h. Plates were washed 4 3 in TBST, then anti-mouse
(Invitrogen) or anti-human (Invitrogen) horseradish peroxidase-conjugated antibodies were diluted 1:5,000 and 25 mL added to
each well and incubated at 37C for 1 h. Plates were washed 4 3 in TBST and 25 mL of TMB (SeraCare) was added to every well
for 5 min at room temperature. The reaction was quenched with the addition of 25 mL of 1 N HCl. Plates were immediately read at
450 nm on a VarioSkanLux plate reader (ThermoFisher) and data plotted and fit in Prism (GraphPad) using nonlinear regression
sigmoidal, 4PL, X is log(concentration) to determine EC50 values from curve fits.
For anti-I53-50 ELISA, 50 mL of 2 mg/mL I53-50A trimer, I53-50B pentamer, or I53-50 particles were plated onto 96-well Nunc
Maxisorp (ThermoFisher) plates in TBS. Plates were incubated at 25C for 1 h then blocked with 200 mL of 2% BSA in TBST for
an additional 1 h at 25C. Plates were washed 3 3 in TBST using a plate washer (BioTek), 1:5 serial dilutions of mouse sera were
made in 50 mL TBST starting at 1:100 and incubated at 25C for 1 h. Plates were washed 33 in TBST, then anti-mouse horseradish
peroxidase conjugated horse IgG (Cell Signaling Technology, #7076S) was diluted 1:2,000 in 2%BSA in TBST and 50 mL was added
to each well and incubated at 25C for 30 min. Plates were washed 3 3 in TBST and 100 mL of TMB (SeraCare) was added to every
well for 2min at room temperature. The reactionwas quenchedwith the addition of 100 mL of 1 NHCl. Plateswere immediately read at
450 nm on a SpectraMaxM5 plate reader (Molecular Devices) and data plotted and fit in Prism (GraphPad) using nonlinear regression
sigmoidal, 4PL, X is log(concentration) to determine EC50 values from curve fits.
Pseudovirus production
MLV-based SARS-CoV-2 S, SARS-CoV S, and WIV-1 pseudotypes were prepared as previously described (Millet and Whittaker,
2016; Walls et al., 2020). Briefly, HEK293T cells were co-transfected using Lipofectamine 2000 (Life Technologies) with an
S-encoding plasmid, an MLV Gag-Pol packaging construct, and the MLV transfer vector encoding a luciferase reporter according
to the manufacturer’s instructions. Cells were washed 3 3 with Opti-MEM and incubated for 5 h at 37C with transfection medium.
DMEM containing 10% FBS was added for 60 h. The supernatants were harvested by spinning at 2,500 g, filtered through a 0.45 mm
filter, concentrated with a 100 kDa membrane for 10 min at 2,500 g and then aliquoted and stored at 80C.
Pseudovirus entry and serum neutralization assays
HEK-hACE2 cells were cultured in DMEM with 10% FBS (Hyclone) and 1% PenStrep with 8% CO2 in a 37
C incubator
(ThermoFisher). One day prior to infection, 40 mL of poly-lysine (Sigma) was placed into 96-well plates and incubated with rotation
for 5 min. Poly-lysine was removed, plates were dried for 5 min then washed 1 3 with DMEM prior to plating cells. The following
day, cells were checked to be at 80% confluence. In a half-area 96-well plate a 1:3 serial dilution of sera was made in DMEM starting
between 1:3 and 1:66 initial dilution in 22 mL final volume. 22 mL of pseudovirus was then added to the serial dilution and incubated at
room temperature for 30-60 min. HEK-hACE2 plate media was removed and 40 mL of the sera/virus mixture was added to the cells
and incubated for 2 h at 37Cwith 8%CO2. Following incubation, 40 mL 20% FBS and 2%PenStrep containing DMEMwas added to
the cells for 48 h. Following the 48-h infection, One-Glo-EX (Promega) was added to the cells in half culturing volume (40 mL added)
and incubated in the dark for 5 min prior to reading on a Varioskan LUX plate reader (ThermoFisher). Measurements were done on all
ten mouse sera samples from each group in at least duplicate. Relative luciferase units were plotted and normalized in Prism
(GraphPad) using a zero value of cells alone and a 100% value of 1:2 virus alone. Nonlinear regression of log(inhibitor) versus normal-
ized responsewas used to determine IC50 values from curve fits.Mann-Whitney tests were used to compare two groups to determine
whether they were statistically different.
Live virus production
SARS-CoV-2-nanoLuc virus (WA1 strain) in which ORF7 was replaced by nanoluciferase gene (nanoLuc), and mouse-adapted
SARS-CoV-2 (SARS-CoV-2 MA) (Dinnon et al., 2020b) were generated by the coronavirus reverse genetics system described
previously (Hou et al., 2020). Recombinant viruses were generated in Vero E6 cells (ATCC-CRL1586) grown in DMEM high glucose
media (GIBCO #11995065) supplemented with 10% Hyclone Fetal Clone II (GE #SH3006603HI), 1% non-essential amino acid, and
1% Pen/Strep in a 37C +5% CO2 incubator. To generate recombinant SARS-CoV-2, seven DNA fragments which collectively
encode the full-length genome of SARS-CoV-2 flanked by a 5¿ T7 promoter and a 3¿ polyA tail were ligated and transcribed
in vitro. The transcribed RNA was electroporated into Vero E6 cells to generate a P0 virus stock. The seed virus was amplified twice
in Vero E6 cells at low moi for 48 h to create a working stock which was titered by plaque assay (Hou et al., 2020). All the live viruse8 Cell 183, 1367–1382.e1–e10, November 25, 2020
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pressure, by operators in Tyvek suits wearing personal powered-air purifying respirators.
Luciferase-based serum neutralization assay, SARS-CoV-2-nanoLuc
Vero E6 cells were seeded at 2x104 cells/well in a 96-well plate 24 h before the assay. One hundred pfu of SARS-CoV-2-nanoLuc
virus (Hou et al., 2020) were mixed with serum at 1:1 ratio and incubated at 37C for 1 h. An 8-point, 3-fold dilution curve was gener-
ated for each sample with starting concentration at 1:20 (standard) or 1:2000 (high neutralizer). Virus and serum mix was added to
each well and incubated at 37C + 5% CO2 for 48 h. Luciferase activities were measured by Nano-Glo Luciferase Assay System
(Promega, WI) following manufacturer protocol using SpectraMax M3 luminometer (Molecular Device). Percent inhibition and
50% inhibition concentration (IC50) were calculated by the following equation: [1-(RLU with sample/ RLU with mock treatment)] 3
100%. Fifty percent inhibition titer (IC50) was calculated in GraphPad Prism 8.3.0 by fitting the data points using a sigmoidal
dose-response (variable slope) curve.
Tetramer production
Recombinant SARS-CoV-2 trimeric Spike was biotinylated using the EZ-Link Sulfo-NHS-LC Biotinylation Kit (ThermoFisher). The
biotinylated protein was then incubated with differing amounts of streptavidin-PE (Prozyme) and probed with SA-AF680 (Invitrogen)
to determine the ratio of biotin to streptavidin at which there was excess biotin available for SA-AF680 to bind. This ratio was used to
determine the concentration of biotinylated Spike protein, allowing for the calculation the amount of SA-PE required to create a 6:1
ratio of Spike to SA-PE. The biotinylated Spike was incubated with SA-APC for 30 min at room temperature and purified on a
Sephacryl S-300 size exclusion column, and the tetramer fraction was centrifuged in a 100-kD molecular weight cutoff Amicon Ultra
filter (Millipore). The tetramer concentration was determined bymeasuring the absorbance of APC at 650 nM. The RBD domain of the
SARS-CoV-2 Spike protein was biotinylated and tetramerized with SA-PE in the same manner, and the concentration was deter-
mined by measuring the absorbance of PE at 565 nM. The APC decoy reagent was generated by conjugating SA-APC to Dylight
755 using a DyLight 755 antibody labeling kit (ThermoFisher), washing and removing unbound DyLight 755, and incubating with
excess of an irrelevant biotinylated His-tagged protein. The PE decoy was generated in the same manner, by conjugating SA-PE
to Alexa Fluor 647 with an AF647 antibody labeling kit (ThermoFisher).
Mouse immunization, cell enrichment, and flow cytometry
For phenotyping of B cells, 6-week old female BALB/c mice, three per dosing group, were immunized intramuscularly with 50 mL per
injection site of vaccine formulations containing 5 mg of SARS-CoV-2 antigen (either S-2P trimer or RBD, but not including mass from
the I53-50 nanoparticle) mixed 1:1 vol/vol with AddaVax adjuvant on day 0. All experimental mice were euthanized for harvesting of
inguinal and popliteal lymph nodes on day 11. The experiment was repeated two times. Popliteal and inguinal lymph nodes were
collected and pooled for individual mice. Cell suspensionswere prepared bymashing lymph nodes and filtering through 100 mMNitex
mesh. Cells were resuspended in PBS containing 2% FBS and Fc block (2.4G2), and were incubated with 10 nM Decoy tetramers at
room temperature for 20 min. RBD-PE tetramer and Spike-APC tetramer were added at a concentration of 10 nM and incubated on
ice for 20 min. Cells were washed, incubated with anti-PE and anti-APCmagnetic beads on ice for 30 min, then passed over magne-
tized LS columns (Miltenyi Biotec). Bound B cells were stained with anti-mouse B220 (BUV737), CD3 (PerCP-Cy5.5), CD138 (BV650),
CD38 (Alexa Fluor 700), GL7 (eFluor 450), IgM (BV786), IgD (BUV395), CD73 (PE-Cy7), andCD80 (BV605) on ice for 20min. Cells were
run on the Cytek Aurora and analyzed using FlowJo software (Treestar). Cell counts were determined using Accucheck cell count-
ing beads.
NHP immunization
APigtail macaquewas immunizedwith 250 mg of RBD-12GS-I53-50 nanoparticle (88 mgRBD antigen) at day 0 and day 28. Bloodwas
collected at days 0, 10, 14, 28, 42, and 56 days post-prime. Bloodwas collected in serum collection tubes and allowed to clot at room
temperature. Serum was isolated after a 15 min spin at 1455 x g for 15 min and stored at80C until use. Prior to vaccination or blood
collection, animals were sedated with an intramuscular injection (10 mg/kg) of ketamine (Ketaset; Henry Schein). Prior to inocula-
tion, immunogen suspensions were gently mixed 1:1 vol/vol with AddaVax adjuvant (Invivogen, San Diego, CA) to reach a final con-
centration of 0.250 mg/mL antigen. The vaccine was delivered intramuscularly into both quadriceps muscles with 1 mL per injection
site on days 0 and 28. All injection sites were shaved prior to injection. Animals were observed daily for general health (activity and
appetite, urine/feces output) and for evidence of reactogenicity at the vaccine inoculation site (swelling, erythema, and pruritus) for up
to 1 week following vaccination. They also received physical exams including temperature and weight measurements at each study
time point. None of the animals became severely ill during the course of the study nor required euthanasia.
Competition Bio-layer Interferometry
Purification of Fabs from NHP serum was adapted from (Boyoglu-Barnum et al., 2020). Briefly, 1mL of day 56 serum was diluted to
10 mL with PBS and incubated with 1 mL of 33 PBS washed protein A beads (GenScript) with agitation overnight at 37C. The next
day beadswere thoroughly washedwith PBS using a gravity flow column and bound antibodies were elutedwith 0.1M glycine pH 3.5
into 1M Tris-HCl (pH 8.0) to a final concentration of 100 mM. Serum and early washes that flowed through were re-bound to beadsCell 183, 1367–1382.e1–e10, November 25, 2020 e9
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buffer (40 mM sodium phosphate pH 6.5, 20 mM EDTA, 40 mM cysteine) was added to concentrated and pooled IgGs. 500 mL of
resuspended immobilized papain resin (ThermoFisher Scientific) freshly washed in 1 3 digestion buffer (20 mM sodium phosphate,
10 mM EDTA, 20 mM cysteine, pH 6.5) was added to purified IgGs in 23 digestion buffer and samples were agitated for 5 h at 37C.
The supernatant was separated from resin and resin washes were collected and pooled with the resin flow through. Pooled super-
natants were sterile-filtered at 0.22 mm and applied 6 3 to PBS-washed protein A beads in a gravity flow column. The column was
eluted as described above and the papain procedure repeated overnight with undigested IgGs to increase yield. The protein A flow-
throughs were pooled, concentrated (Amicon 10 kDa), and buffer exchanged into PBS. Purity was checked by SDS-PAGE.
Epitope competition was performed and analyzed using BLI on an Octet Red 96 System (Pall Forté Bio/Sartorius) at 30C with
shaking at 1000 rpm. NTA biosensors (Pall Forté Bio/Sartorius) were hydrated in water for at least 10 min, and were then equilibrated
in 10 3 Kinetics buffer (KB) (Pall Forté Bio/Sartorius) for 60 s. 10 ng/mL monomeric RBD in 10 3 KB was loaded for 100 s prior to
baseline acquisition in 103KB for 300 s. Tips were then dipped into diluted polyclonal Fab in 103KB in a 1:3 serial dilution beginning
with 5000 nM for 2000 s or maintained in 103 KB. Tips bound at varying levels depending on the polyclonal Fab concentration. Tips
were then dipped into the same concentration of polyclonal Fab plus either 200 nM of hACE2, 400 nM CR3022, or 20 nM S309 and
incubated for 300-2000 s. The data were baseline subtracted and aligned to pre-loadingwith polyclonal Fabs using the Pall Forté Bio/
Sartorius analysis software (version 12.0) and plotted in PRISM.
ELISpot
96-well ELISpot plates (Millipore) were coated with 20 mg/mL of recombinant SARS-CoV-2 RBD diluted in PBS and incubated at 4C
overnight. Plates were washed with PBS-T (PBS containing 0.05% Tween-20) and blocked with 1%BSA and 5% sucrose in PBS for
2 h at room temperature (RT). Bone marrow was harvested from immunized mice and following red blood cell lysis, cells were plated
onto coated ELISpot plates and incubated at 37C for 5 h. Cells were washed off and antibody secreting cells were detected using
IgG Biotin (BioLegend) followed by SA-AP (R&D Systems). Spots were developed using BCIP/NBT and were counted and analyzed
using the CTL ELIspot reader and Immunospot analysis software (Cellular Technology Limited). Non-specific/background spots
were determined by wells containing no cells. The number of spots detected per well was used to calculate the spot frequency
per 10,000 cells.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details of experiments can be found in the figure legends and in Data S4. For mouse ELISAs and neutralization experi-
ments, sera from 5 (KyMAb) or 10 (BALB/c) animals (or 2 animals when others were euthanized) were used and experiments were
completed in at least duplicate. Geometric mean titers were calculated. Mann-Whitney tests were performed to compare two groups
to determine whether they were statistically different for ELISA and neutralization experiments. For flow cytometry, 3 mice per group
were analyzed in duplicate and cell counts were determined using Accucheck cell counting beads. Statistical significance was deter-
mined by one-way ANOVA, and Tukey’s multiple comparisons tests were performed for any group with a p value less than 0.05.
Significance is indicated with stars: *, p < 0.05; **** p < 0.0001.e10 Cell 183, 1367–1382.e1–e10, November 25, 2020
Supplemental Figures
(legend on next page)
ll
OPEN ACCESSArticle
Figure S1. Additional characterization of RBD Nanoparticle Immunogens, Related to Figure 1
(A) Size exclusion chromatography of RBD-I53-50 nanoparticles, unmodified I53-50 nanoparticle, and trimeric RBD-I53-50A components on a Superose
6 Increase 10/300 GL.
(B) SDS-PAGE of SEC-purified RBD-I53-50 nanoparticles under reducing and non-reducing conditions before and after one freeze/thaw cycle.
(C) Dynamic light scattering of RBD-I53-50 nanoparticles before and after one freeze/thaw cycle indicates monodisperse nanoparticles with a lack of detectable
aggregates in each sample.
(D) Hydrogen/Deuterium-exchange mass spectrometry analysis, represented here as heatmaps, reveals the structural accessibility and dynamics of the RBD
(PDB 6W41). Color codes indicate deuterium uptake levels. Monomeric RBD and RBD-8GS-I53-50A have indistinguishable uptake patterns, and are presented in
a single heatmap at each time point.
(E) Top, bar graphs reveal similar glycan profiles at the N-linked glycosylation sites N331 and N343 in five protein samples: monomeric RBD, S-2P trimer, RBD-
8GS-, RBD-12GS-, and RBD-16GS-I53-50A trimeric components. Bottom, comprehensive glycan profiling on other N-linked glycosylation sites besides N331
and N343 that are found in the S-2P trimer. The axis of each bar graph is scaled to 0%–80%. M9 to M5, oligomannose with 9 to 5 mannose residues, are colored
green. Hybrid and FHybrid, hybrid typeswith or without fucosylation, are blue. Subtypes in complex type, shown in pink, are classified based on antennae number
and fucosylation (Harvey et al., 2011).
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Figure S2. Determination of hACE2 and CR3022 Fab Affinities by Biolayer Interferometry, Related to Table 1
(A) Analysis of monomeric hACE2 binding to immobilized monomeric RBD and trimeric RBD-8GS-, RBD-12GS-, and RBD-16GS-I53-50A components.
(B) Analysis of CR3022 Fab binding to immobilized monomeric RBD and trimeric RBD-8GS-, RBD-12GS-, and RBD-16GS-I53-50A components.
Affinity constants (Table 1) were determined by global fitting of the kinetic data from six analyte concentrations to a 1:1 binding model (black lines).
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Figure S3. Characterization of Partial Valency RBD Nanoparticles, Related to Figure 2
(A) Representative electronmicrographs of negatively stained RBD-8GS-, RBD-12GS-, and RBD-16GS-I53-50 nanoparticles displaying the RBD at 50%valency.
The samples were imaged after one freeze/thaw cycle. Scale bars, 100 nm.
(B) SDS-PAGE of purified RBD-8GS-, RBD-12GS-, and RBD-16GS-I53-50 nanoparticles displaying the RBD at 50% valency. Both RBD-bearing and unmodified
I53-50A subunits are visible on the gels.
(C) DLS of 50% valency RBD-8GS-, RBD-12GS-, and RBD-16GS-I53-50 nanoparticles both before and after freeze/thaw. No aggregates or unassembled
components were observed.
(D) UV/vis absorption spectra of 50% valency RBD-8GS-, RBD-12GS-, and RBD-16GS-I53-50 nanoparticles. Turbidity in the samples is low, as indicated by the
low absorbance at 320 nm.
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Figure S4. Day 28 Stability Data, Related to Figure 3
(A) SDS-PAGE of purified monomeric RBD, S-2P trimer, RBD-I53-50A components and RBD-12GS-I53-50 nanoparticle in reducing and non-reducing condi-
tions. No degradation of any immunogen was observed after a four-week incubation at any temperature analyzed.
(B) Analysis of mACE2-Fc and CR3022 IgG binding to monomeric RBD, RBD-I53-50A trimeric components, and RBD-12GS-I53-50 nanoparticle by BLI after a
four-week incubation at three temperatures. Monomeric RBD was used as a reference standard in nanoparticle component and nanoparticle BLI experiments.
The RBD-12GS-I53-50 nanoparticle lost minimal binding at the higher temperatures after four weeks; the remaining antigens did not lose any mACE2-Fc or
CR3022 IgG binding over the course of the study.
(C) UV/vis spectroscopy showed minimal absorbance in the near-UV, suggesting a lack of aggregation/particulates after a four week-incubation at three
temperatures, with the exception of S-2P trimer, which gained significant absorbance around 320 nm at ambient temperature. RBD-12GS-I53-50 nanoparticle
samples at 22-27C at several earlier time points exhibited similar peaks near 320 nm (see Data S2).
(D) nsEM of RBD-12GS-I53-50 nanoparticle (top) and S-2P trimer (bottom) after a 4-week incubation at three temperatures. Intact monodisperse nanoparticles
were observed at all temperatures, with no observed degradation or aggregation. The S-2P trimer remained well folded in the < -70C and 22-27C samples, but
was unfolded in samples incubated at 2-8C. Scale bars: RBD-12GS-I53-50, 100 nm; S-2P, 50 nm.
(E) DLS of the RBD-12GS-I53-50 nanoparticle after a four-week incubation at three temperatures. No aggregation was observed at any temperature.
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Figure S5. Subclasses of Vaccine-Elicited Abs and Anti-scaffold Antibody Titers, Related to Figure 4
Levels of vaccine-elicited IgG specific to the (top) trimeric I53-50A component, (middle) pentameric I53-50B component, and (bottom) assembled I53-50
nanoparticle two weeks post-prime (left) and post-boost (right) in BALB/c mice. Data are plotted as in Figure 4 and are representative data from technical
replicates that were performed at least twice.
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Figure S6. B Cell Gating Strategy and Durability of the Vaccine-Elicited Immune Response, Related to Figures 4, 5, and 6
(A) Representative gating strategy for evaluating RBD-specific B cells, germinal center (GC) precursors and B cells (CD38+/–GL7+), and B cell isotypes. Top row,
gating strategy for measuring numbers of live, non-doublet B cells. These cells were further analyzed as depicted in the middle and bottom rows. Middle row,
representative data from amouse immunized with themonomeric RBD formulatedwith AddaVax. RBD+CD38+/–GL7+ cells that did not bind decoys were counted
as antigen-specific GC precursors and B cells. Bottom row, representative data from a mouse immunized with the RBD-12GS-I53-50 nanoparticle formulated
with AddaVax. GC precursors and B cells were further analyzed to characterize B cell receptor isotypes.
(B and C) Levels of (B) S-specific IgG and (C) pseudovirus neutralization in sera collected 20 (RBD-16GS-I53-50) or 24 (monomeric RBD, S-2P, RBD-8GS-I53-50,
and RBD-12GS-I53-50) weeks post-boost. Sera were collected from the two animals from each group that were not challenged with MA-SARS-CoV-2. Data are
plotted as in Figures 4 and 5.
(D) Numbers of S-2P–specific Ab secreting cells in the bone marrow of BALB/c mice immunized with either S-2P trimer or RBD-16GS-I53-50 nanoparticle,
measured by ELISpot. Cells were harvested 17 weeks post-boost (see panel B inset). The animal experiment was performed once. Statistical significance was
determined by two-tailed unpaired t test. *p = 0.02.
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